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 Modular polyketide synthase (PKS) pathways generate a diverse array of 
pharmaceutically significant small molecule natural products, and synthetic PKS biology 
may facilitate pharmaceutical development, production of industrially important 
compounds, and discovery of chemoenzymatic reagents. Of interest to these efforts are 
biosynthetic schemes that install unusual functional groups, including “β-branching” 
enzymes that generate alkyl substituents found in some polyketides. PKS enzymes act 
on substrates linked to acyl carrier proteins (ACP) via a phosphopantetheine arm 
(Ppant), but β-branching enzymes are further selective for an intermediate linked to a 
specialized, branch-acceptor ACP (ACPA). ACP-enzyme interactions are a poorly 
understood facet of PKS biology and selectivity of β-branching enzymes for ACPA is 
essential for fidelity of the biosynthetic pathway. 
A hydroxymethylglutaryl synthase (HMGS) initiates β-branching using an acetyl 
nucleophile that is delivered to HMGS by a distinct, branch-donor ACP (ACPD). This 
thesis summarizes research into the structural basis for the distinct selectivity of HMGS 
for its acetyl-ACPD and polyketide-ACPA substrates. We solved crystal structures of 
HMGS and determined features that both distinguish it from its primary metabolism 
homolog and are involved in ACP interaction. Structures of the ACPD/HMGS complex 
revealed that ACPD recognition is dependent on electrostatic interactions and on unique 
 ix 
structural features of ACPD. In these first structures of a natively bound PKS 
ACP/enzyme complex, we discovered that ACPD Ppant positioning is substrate 
dependent and identified distinct pre- and post-reaction positions of the Ppant. 
Furthermore, differences in the ACPA and ACPD interactions with HMGS apparently 
result in different Ppant positions that we selectively disrupted with active site 
substitutions. Finally, we demonstrated that HMGS is reactive with a non-natural donor-
substrate, which has promising implications for the use of HMGS in synthetic biology 







Chapter 1. Background and introduction 
 
Significance, enzymology, and engineering of polyketide synthase pathways 
From the use of herbal remedies to modern pharmaceuticals, natural products 
have been at the center of medicine since antiquity. Natural products and their 
derivatives make up half of approved pharmaceuticals and encompass diverse chemical 
scaffolds that have found use in virtually every category of therapeutic1. These bioactive 
small molecules often have complex structures, containing several stereocenters and/or 
unusual functional groups. While natural products can be difficult to produce 
synthetically, in many cases they can be cheaply produced by fermentation or semi-
synthetic means. Due to this difficulty of total synthesis, much effort has been invested 
in engineering natural product biosynthetic pathways to produce altered molecules that 
may have improved pharmaceutical properties, however, such engineered pathways are 
often marred by diminished throughput. By understanding enzymology of the 
biosynthetic pathway one may facilitate engineering of processive pathways. 
Fungi, plants, and bacteria, all contain polyketide synthases (PKS), which have 
been a major focus of engineering efforts due to their capacity to assemble acyl-CoA 
building blocks into complex molecules2,3. Modular polyketide synthases are a PKS 
subclass that form enzyme assembly lines4–6, where each module is a set of fused 
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enzymes that extend the nascent polyketide by two carbons and perform chemical 
modifications after each building block is incorporated  (Figure 1.1). Different 
modifications can be made at each point in the pathway, depending on the modification 
domains present in the corresponding module. An acyl-carrier protein domain (ACP) 
tethers intermediates via a post-translationally added phosphopantetheine arm (Ppant), 
shuttles them between different catalytic domains of a module, and transfers the 
finished product to the next module of the pathway.  
The catalytic sequence of each PKS module is loading, extension, modification, 
and transfer to the next module4 (coinciding with that module’s extension). A summary 
of these reactions and the intermediates they generate is provided in Figure 1.2. The 
ACP is loaded by transthioesterification of an acyl group from an acyl-CoA to the Ppant 
arm, which is catalyzed by an acyltransferase domain (AT). ATs may occur as a domain 
within each module (cis-AT pathways5), or as a standalone enzyme that acts in trans on 
each ACP within the pathway (trans-AT pathways6). During extension, the ketosynthase 
domain (KS) accepts the nascent polyketide from the ACP of the previous module 
(upstream ACP) to a conserved cysteine in the active site. The ketosynthase then 
decarboxylates the malonyl or methylmalonyl-loaded ACP from within the module during 
a Claisen condensation that results in a β-keto intermediate tethered to the downstream 
ACP. The β-keto intermediate is either subject to α-methylation and/or reduction, or to 
β-branching. At the end of the pathway, the polyketide is released from the final ACP by 
a thioesterase (TE) domain. Many TEs catalyze cyclization of the polyketide to 
hydrolyze it from the Ppant. Finally, modifications are often made to the polyketide after 
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offloading, such as the glycosylations that are present in the biosynthesis of macrolide 
antibiotics. 
 
Figure 1.1 Architecture of modular PKS. A. The PKS pathway that generates 
pikromycin, a macrolide antibiotic, consists of 7 modules outlined in black. The 
intermediate generated by each module is shown tethered to that module’s ACP, and 
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the final product is generated from cyclization by the TE and glycosylation. B. mFAS7 
(2VZ8), for a long time, was a model for the architecture of domains with in a module. A 
cryo EM structure of PikAIII8 revealed that the module adopts an an arch-like 
arrangement and that the ACP (yellow) repositions depending on the intermediate that it 
tethers. A recent model of a mycocerosic acid PKS module9 suggests a FAS like 
architecture for fully reducing modules (containing the full KR-DH-ER reductive 
sequence). See Figure 1.2 for reactions catalyzed by each enzymatic domain. 
 
While there are structures for many of these domains commonly found in PKS 
modules10, information on substrate selectivity and the architecture of the module is still 
limited. For a long time, the best model for the domain architecture of a PKS module 
was fatty-acid synthase (FAS, Figure 1.1), which was supported by crystal structures of 
KS-AT didomains11–13. The cryo-EM structure of PikAIII (Figure 1.1) turned this 
paradigm on its head, and captured a new, arch-like arrangement for a KS-AT-KR-ACP 
module8,14. Crucially, these structures also revealed a new entrance to the KS active 
site to which the intramodular ACP can dock for the extension reaction. This structure 
may not be the end of the story though, as indicated by a recent study of a mycocerosic 
acid synthase-like PKS module (MAS), which contained a full DH-ER-KR reductive 
suite, unlike PikAIII. Independent structures of the KS-AT didomain and DH-ER-KR 
tridomain both revealed FAS-like arrangements for each multidomain9. 
Currently, prospects for engineering new PKS pathways with the goal of creating 
custom molecules or libraries of molecules are grim, though success has been found 
with more limited goals2,3,15. Conservative changes, such as point mutations to 
individual domains or domain swaps, have been the most successful2. Combinatorial 
approaches sometimes result in compatible sequences of a few modules16, but the rules 
determining why some combinations of modules have throughput and others don’t are 
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still unknown. Finally, some studies aimed at engineering PKS dimodules to produce 
biofuels and molecules of industrial interest have had success as a proof of principle17. 
An additional concern for synthetic biology is that the natural producers of these 
molecules are often unculturable, necessitating the use of a heterologous host in which 
to express the pathway. 
Some pathways include β-alkylations, referred to a “β-branches”, where the β-
keto intermediate produced by a module with no reductive modification domains may be 
substituted with a β-alkyl, most commonly a methyl18. β-branching is catalyzed by a set 
of standalone enzymes that are almost always encoded by a β-branching cassette that 
follows the gene for the module that accepts the branch. For virtually every step of the 
PKS catalytic cycle, a variation or non-canonical activity can be found in nature, which 
increases the vast chemical space accessible by PKS pathways. KR domains can 
generate either stereochemistry of a β-hydroxyl and DH domains can create cis, trans, 
and even β-γ double bonds, for example. β-branching may be the most versatile of 
these modification schemes, as changing the enzymes encoded by the β-branching 
cassette can lead to incorporation of exotic and seldom-seen functional groups into the 




Figure 1.2 Reactions catalyzed by PKS domains. Domains within the same module 
are depicted as unfilled circles, while the upstream ACP is shown in gray. β-branching 
enzymes, which act in trans are shown as squares. R corresponds to the remainder of 
the polyketide intermediate, R’ to the α-methyl or hydrogen (depending on the use of 




Figure 1.3 Flowchart of polyketide β-branching. The canonical enzymatic sequence 
that generates a methyl branch is outlined. Branch atoms are shown in red. Alternative 
branch processing steps are labeled in italics. Alternative branch processing involving 
halogenation, as occurs in curacin A and jamaicamide branching19 is boxed in green. 
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Use of a propionyl donor by HMGS, as occurs in myxovirescin20 and leinamycin21 
branching is boxed in yellow. The bryostatin and leinamycin β-branches (gray box) are 
highly unusual and the processing steps that generate them have not been conclusively 
determined. 
 
Polyketide diversification by β-branching  
Just as each module follows the pattern of a conserved extension step followed 
by variable extension steps to produce the different functional groups that decorate a 
polyketide natural product, β-branching proceeds by a conserved branch initiation step, 
followed by variable branch modification steps that tailor the final structure of the β-alkyl 
substituent18 (Figure 1.3). The branch carbon originates from an acetyl group, or, rarely, 
a propionyl, that is tethered by a specialized donor ACP (ACPD) encoded in the β-
branching cassette. The ACP that tethers the polyketide intermediate subject to 
branching is referred to as the acceptor ACP (ACPA). Often, β-branching will happen at 
only one point in the biosynthetic pathway, though some pathways have as many as 
five branches22,23, and, very rarely, such pathways may install different branches. A 
common, hydroxymethylglutaryl-like (HMG) intermediate is the starting point for the 
branch modification enzymes, which is formed from the activity of a 
hydroxymethylglutaryl synthase (HMGS)24,20,25 (Figure 1.3). The following is a 
discussion of the reactions catalyzed by each enzyme associated with β-branching and 
how they contribute to the formation of diverse branches. 
i. pre-branching enzymes. The acetyl branch unit is generated by decarboxylation 
of malonyl-ACPD by a decarboxylating ketosynthase (KSDC)18,24,20. KSDC sequences are 
highly divergent compared to non-branching KSs, but they all have a conserved serine 
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substitution for the KS catalytic cysteine. The KSDC is often encoded with HMGS in a 
polycistronic gene26–28. In the leinamycin pathway, which generates an ethyl branch, a 
malonyl-CoA decarboxylase-like enzyme replaces KSDC and decarboxylates a 
methymalonyl-ACPD, producing a propionyl-ACPD substrate for HMGS29,21. Finally, the 
question of how ACPD is loaded with malonyl or methylmalonyl is open in most cases. 
For some trans-AT pathways, the AT has been shown to be capable of loading 
ACPD24,20. An embedded AT is often proposed to load ACPD in cis-AT pathways, but this 
hypothesis is untested. 
ii. Hydroxymethylglutaryl synthases. HMGS generates the initial branch by the 
aldol addition of an acetyl donor to a β-keto polyketide acceptor, forming an HMG-like 
product (Figure 1.3). It is homologous to HMG-CoA synthase (HMGCS), a primary 
metabolism enzyme of the mevalonate isoprenoid biosynthesis pathway30, which 
catalyzes the same reaction as HMGS, but with CoA-tethered substrates31. ACPD 
delivers the acetyl branch-unit to a cysteine in the HMGS active site, which is 
subsequently converted to an enolate. After HMGS interacts with the acceptor ACP 
(ACPA), the enolate attacks the β-carbon of the β-keto polyketide acceptor, forming the 
carboxymethyl branch. In rare cases, a specialized HMGS may use a propionyl donor-
acyl, resulting in an ethyl branch20,29,21. 
iii. ECH1 dehydratases. β-branching cassettes often encode two enoyl-CoA 
hydratase-like enzymes that dehydrate and decarboxylate the HMG-like initial branch32. 
ECH1 dehydrates the β-carbon to generate an α-β unsaturated 3-R-glutaconyl 
intermediate. β-branching during bryostatin biosynthesis creates unusual O-methyl-
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carboxyvinyl branches that have “β-γ” double bonds, but it is unclear whether these 
result from a non-canonical activity of the bryostatin ECH1 or from the activity of another 
processing enzyme25,33. 
iv. ECH2 decarboxylases. The second ECH decarboxylates the γ-carbon of the 
ECH1 product32 (this corresponds to the carboxylate of the acetyl added by HMGS) to 
generate a 3-methylcrotonyl-like intermediate. This is often the final step of β-branching, 
after which the branched intermediate is delivered to the KS of the next module in the 
pathway. ECH2 is proposed to decarboxylate its 3-R-glutaconyl substrate first, resulting 
in an enolate intermediate that is stabilized by an oxyanion hole34. Canonically, the 
enolate intermediate collapses and is reprotonated at the γ-position, producing and α-β 
unsaturated product. In several cases18, ECH2 instead reprotonates at the α-position to 
generate a vinyl branch. Unfortunately crotonase enzymes like ECH2 have notoriously 
poor active site conservation and the identity of the catalytic acid for these non-
canonical ECH2s is unclear34,35. 
v. Enoylreductases. In some pathways, the methylcrotonyl product of ECH2 is 
further reduced by an enoylreductase domain. While most ERs simply saturate the α,β 
positions, the curacin A pathway encodes an unusual ER that executes a 
cyclopropanation reaction by eliminating a chloride added to the branch carbon by a 
halogenase19. The structure of the curacin A ER is known and structural motifs in the 
ER active site were identified that are specific to cyclopropanase activity36. 
vi. Halogenases. The curacin A halogenase chlorinates the branch carbon to 
allow the cyclopropanation reaction, but the jamaicamide pathway also uses a β-
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branching halogenase to create a vinyl-chloride branch19,37,38. In both cases, the 
halogenase enzyme is a domain in the same module as ACPA. The pathways diverge at 
the decarboxylation step and the jamaicamide ECH2 generates a non-canonical β-γ 
double bond as the final step of branching. Interestingly the jamaicamide ER is active 
and able to reduce an α-β unsaturated substrate, but cannot reduce the β-γ unsaturated 
vinyl-chloride branch19. 
vii. Other modification enzymes. The final step of bryostatin branching is 
catalyzed by an O-methyltransferase, which methylates the carboxylates of both O-
methyl-carboxyvinyl branches33. A few pathways encode enzymes that tailor the final β-
branch structure after the polyketide is offloaded from the assembly line. In 
myxovirescin biosynthesis, a P450 hydroxylates the methyl branch and that hydroxyl is 
then methylated by and O-MT20,39. Finally, several pathways40–42 install unusual epoxide 
branches. This requires a non-canonical ECH2 to generate vinyl branches, which are 
then converted to epoxides by a diooxygenase41. 
Branching ACPs and orchestration of β-branching 
 β-branching requires several enzymes to act in trans on an ACP-tethered 
substrate, whereas most other PKS enzymes act in cis on the ACP fused within their 
respective module. Handoff of the polyketide intermediate from an ACP to the KS of the 
next module sometimes requires the interaction of those two domains in trans, but this 
is facilitated by docking domains appended to the ACP and KS that enhance affinity and 
ensure pairing of the ACP with the correct KS12,43,44. Docking domains are not present 
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on the trans-acting enzymes to efficiently target them to ACPA, implying a different 
mechanism for how β-branching is targeted to a specific module in the assembly line.  
 ACPA and ACPD are specialized for their roles in β-branching. ACPD sequences 
clade separately from other PKS ACPs, and ACPD is a standalone domain. ACPAs have 
a conserved tryptophan in the hydrophobic core that also allows them to be 
distinguished from other ACPs by sequence45. The tryptophan occurs 6 residues after 
the Ppant serine and packs between helix II and helix III in the ACP. These helices 
define a surface commonly associated with enzyme interaction46,47. ACPAs also often 
occur as tandem di- or tri-domains, whereas non-branching ACPs are always single 
domains. Tandem ACP di- and tri-domains enhance the efficiency of β-branching in 
vitro and in vivo48,49. Inactivation of one or more ACPs in a multidomain protein 
decreases catalytic throughput, but the presence of the dead ACPs increases 
throughput relative to a single ACP49. Thus, these multidomains may create a high 
effective concentration to promote the successive reactions of standalone β-branching 
enzymes on the ACPA-tethered substrate. Whereas ACPA is specialized in a way that 
allows it to interact with both the β-branching enzymes as well as KS and AT domains, 
ACPD needs to be specialized such that it  interacts only with the β-branching KSDC, 
HMGS, and whatever domain primes the Ppant arm with a malonyl substrate (or 
methylmalonyl). 
 HMGS plays a critical role as the initiating enzyme of β-branching that 
establishes the chemical platform upon which the other β-branching enzymes act. 
HMGS is a homolog of KS domains, and similarly it must selectively and sequentially 
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interact with distinct ACPs. For the KS, selectivity is mediated by discrete active site 
entrances and docking domains, which localize the upstream ACP to its cognate 
entrance. HMGS likely achieves its high ACP selectivity exclusively by direct protein-
protein interaction with ACPD and ACPA. Swapping the donor and acceptor substrates 
between ACPD and ACPA results in diminished or abolished HMGS activity, and HMGS 
is non-reactive when a non-branching associated ACP from the same biosynthetic 
pathway delivers the acceptor substrate24,20,25. Taken together, these data are strongly 
suggestive that distinguishing structural motifs of ACPD and ACPA enable them to make 
protein-protein interactions with HMGS that are adapted to their respective roles in the 
HMGS mechanism. It is unknown whether HMGS, like the KS, has distinct active site 
entrances to accomplish this. 
 Due to the extreme versatility of β-branching, understanding the rules that allow it 
to proceed efficiently should naturally be a goal of synthetic biology. As with PKS 
modules, individual enzymes and their mechanisms are generally well understood, but 
architectural details are sparse. In particular, little is known about enzyme-ACP 
interactions, which are even more crucial for standalone β-branching enzymes than 
module enzymes that are fused to the ACP. Sequence motifs that acceptor ACPs have 
been identified but it is not understood how these allow ACPA, but not other ACPs, to 
interact with β-branching enzymes. Even more puzzling is HMGS, which needs to 





 This work focuses on how structural elements of HMGS, ACPD, and ACPA 
influence substrate selectivity during β-branching initiation. Chapter 2 describes the 
structure of the curacin A HMGS and ACPD, and how the two proteins interact both pre- 
and post-acetyl transfer, as adapted from Maloney et. al. PNAS. 2016. Next, chapter 3 
describes the role that residues which were observed to be important to the HMGS-
ACPD interaction play in the ACPA interaction. Conserved residues that surround the 
HMGS active site, and were not observed to interact with ACPD, are also studied here to 
evaluate whether they may be important for ACPA docking to HMGS. Finally, chapter 4 
covers donor-acyl selectivity by HMGS. Several substitutions based on HMGSs that use 
a propionyl donor were made to the curacin A HMGS to determine whether they confer 






Chapter 2. HMGS structure and interaction with ACPD 
This chapter is published as: Maloney FP, Gerwick L, Gerwick WH, Sherman DH, and Smith JL. Anatomy 
of the β-branching enzyme of polyketide biosynthesis and its interaction with an acyl-ACP substrate. 
PNAS. 113. 10316-10321 (2016) 
 
Summary 
 Alkyl branching at the β position of a polyketide intermediate is an important 
variation on canonical polyketide natural product biosynthesis. The branching enzyme, 
3-hydroxy-3-methylglutaryl synthase (HMGS), catalyzes the aldol addition of an acyl 
donor to a β-keto-polyketide intermediate acceptor. HMGS is highly selective for two 
specialized acyl carrier proteins (ACP) that deliver the donor and acceptor substrates. 
The HMGS from the curacin A biosynthetic pathway (CurD) was examined to establish 
the basis for ACP selectivity. The donor ACP (CurB) had high affinity for the enzyme (Kd 
0.5 µM) and could not be substituted by the acceptor ACP. High-resolution crystal 
structures of HMGS alone and in complex with its donor ACP reveal a tight interaction 
that depends on exquisite surface shape and charge complementarity between the 
proteins. Selectivity is explained by HMGS binding to an unusual surface cleft on the 
donor ACP, in a manner that would exclude the acceptor ACP. Within the active site, 
HMGS discriminates between pre- and post-reaction states of the donor ACP. The free 
phosphopantetheine (Ppant) cofactor of ACP occupies a conserved pocket that 
excludes the acetyl-Ppant substrate. In comparison to HMG-coenzyme A (CoA) 
synthase, the homologous enzyme from primary metabolism, HMGS has several 
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differences at the active site entrance, including a flexible-loop insertion, which may 
account for the specificity of one enzyme for substrates delivered by ACP and the other 
by CoA.  
Introduction 
 Polyketides are a large and chemically diverse group of natural products that 
includes many pharmaceuticals with a broad range of biological activities and 
applications as antibiotics, antifungals, anti-inflammatory drugs, and cancer 
chemotherapeutic agents50. Polyketide synthase (PKS) biosynthetic pathways are 
subjects of efforts to engineer diversification of natural products in pursuit of 
pharmaceutical leads and compounds of industrial importance2. They are rich sources 
for development of chemo-enzymatic catalysts based on PKS enzymes with unusual 
catalytic activities.  
 Modular type-I PKS pathways, among the most versatile of nature’s systems, are 
biosynthetic assembly lines composed of modules that act in a defined sequence to 
produce complex products with a variety of functional groups and chiral centers. Each 
module is a set of fused catalytic domains that extend and modify a polyketide 
intermediate. Biosynthesis proceeds from intermediates tethered to acyl carrier protein 
(ACP) domains via a thioester link to a phosphopantetheine (Ppant) cofactor. A 
ketosynthase (KS) domain catalyzes extension of the intermediate, and subsequent 
modification domains typically catalyze reduction and/or methylation of the β-keto (3-
keto) extension product. Beyond the enzymes for these core reactions, many PKS 
pathways also include other catalytic functionality. Among the most interesting of these 
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non-canonical capabilities is alkylation at the β position by a set of β-branching 
enzymes18. A 3-hydroxymethylglutaryl (HMG) synthase enzyme (HMGS) catalyzes the 
key branch-incorporation step, generating a β-hydroxy, β-carboxyalkyl acyl-ACP (Figure 
2.1). The final structure of a β-branch depends on the carboxyalkyl group and the series 
of enzymatic steps that tailor the initial branch generated by HMGS18. 
 The natural product curacin A, produced by the marine cyanobacterium Moorea 
producens28, has cytotoxic activity and has been explored as an anticancer agent51. The 
hybrid PKS/NRPS (non-ribosomal peptide synthetase) pathway for curacin A contains 
an abundance of unique enzymes that install distinctive functional groups52, including a 
cyclopropane ring formed by a surprising variation of the β-branching process19. In 
curacin A β-branching, the initial HMG-ACP intermediate undergoes chlorination, 
dehydration, and decarboxylation before a reductive ring-closing reaction generates the 
final cyclopropane group19 (Figure 2.2).  
HMGS is a homolog of the KS extension enzyme in PKS pathways but it is more 
closely related to HMG-coenzyme A (CoA) synthase (HMGCS), an enzyme of primary 
metabolism in the mevalonate-dependent isoprenoid pathway, where it acts directly 
before HMG-CoA reductase30. HMGCS generates HMG-CoA from acetyl-CoA and 
acetoacetyl-CoA by an aldol addition (Figure 2.2). The acetyl group is transferred to a 
catalytic cysteine, then deprotonated by a conserved glutamate. The resulting enolate 
nucleophile attacks the β-carbonyl of the second substrate, acetoacetyl-CoA. The 
covalent enzyme-product complex is hydrolyzed to release HMG-CoA. HMGCS is well 
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characterized, including crystal structures of complexes between the enzyme and its 
product, substrates, and inhibitors53–58.  
 
Figure 2.1 HMGS reaction. A. Reaction steps. 1) ACPD transfers an acetyl group to 
HMGS Cys114 and Glu82 deprotonates the acetyl group; 2) the resulting enolate 
nucleophile attacks acetoacetyl-ACPA; 3) The HMG-ACPA product is hydrolyzed from 
Cys114. R indicates the polyketide intermediate (methyl in curacin A biosynthesis). B. 




Figure 2.2 A. Curacin A β-branching. CurC KSDC is proposed to decarboxylate 
malonyl-CurB, generating acetyl-CurB (ACPD), 1. CurD HMGS catalyzes formation of 
HMG-CurA ACP3 (ACPA), 2. CurA Hal chlorinates the γ-carbon of HMG-ACPA, which is 
subsequently dehydrated to 3 and decarboxylated to 4 by CurE ECH1 and CurF ECH2, 
respectively. CurF ER catalyzes cyclopropanation to 6 by NADPH-dependent addition of 
hydride and elimination of chloride. B. HMGCS Reaction.  HMG-CoA synthase 
generates HMG-CoA from acetyl- and acetoacetyl-CoA via an aldol addition. 
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The HMGS and HMGCS reactions (Figure 2.1) are analogous and, in the case of 
the curacin A HMGS (CurD), have identical acyl substrates that are tethered to distinct 
ACPs and not to CoA. Whereas HMGCS distinguishes acetyl-CoA and acetoacetyl-CoA 
based on the acyl group and the acetylation status of the catalytic cysteine, HMGS also 
displays ACP selectivity: a standalone acetyl “donor” ACP (ACPD), and an acetoacetyl-
like “acceptor” ACP (ACPA) bearing the polyketide intermediate within a specific module 
of the PKS pathway20,25. HMGS enzymes are highly selective for acetoacetyl-ACPA and 
acetyl-ACPD, and do not react with CoA substrates24,20,25. At the sequence level, the 
donor and acceptor ACPs clade separately from each other and from non-branch ACPs 
from the same pathways25,45. Thus, by selecting for the correct acyl-ACPs, HMGS 
prevents the formation of aberrantly branched metabolites. 
The basis of ACP selectivity by HMGS is unknown, and detailed views of ACP 
interactions with PKS enzymes are few. The homologous KS extension enzymes 
distinguish their cognate donor and acceptor ACPs through two active site entrances8 in 
interactions facilitated by fusion or non-covalent interaction of appended docking 
domains43,44, which are absent in HMGS. HMGS selectivity for ACPA and ACPD 
presumably originates from distinguishing features of each ACP that result in different 
modes of interaction with HMGS. Here we present the biochemical characterization of 
the curacin A HMGS (CurD) and the interaction with its cognate ACPD (CurB). Crystal 
structures of HMGS and of complexes with ACPD reveal a striking shape 
complementarity between the proteins and specific charge interactions that orient the 
Ppant cofactor in the HMGS active site. Pre- and post-acetyl transfer states of Ppant 
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capture sequential views of the catalytic cycle. The results are a detailed benchmark of 
high-affinity enzyme-ACP interactions that advance our understanding of enzyme 
selectivity for carrier proteins. 
 
Results 
CurD HMGS activity. Purified, recombinant ACPD (CurB) and the second 
cognate ACPA from the CurA tandem ACPA tridomain (Figure 2.2) were acylated in vitro. 
Recombinant CurD HMGS converted 83% of equimolar acetyl-ACPD and acetoacetyl-
ACPA to HMG-ACPA in a 10 minute reaction at 25 °C (Table 2.1). Reaction progress 
was monitored by LC-MS using the acyl-Ppant ejection assay59 (Figure 2.3, Table 2.2). 
We detected no conversion of acetoacetyl-ACPA to HMG-ACPA when the catalytic 
Cys114 was substituted with serine (Table 2.2). The C114S substitution also prevented 
acetyl transfer from acetyl-ACPD (Table 2.3). 
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HMGS and crystallization variant3 
Wild type 82.8 ± 0.3 1.1 ± 0.1 0.5 ± 0.2 
AAA3 87 ± 1 -- -- 
Mismatched acyl-ACP substrates5 
ACPD as donor 
and acceptor 29 ± 2 -- -- 
ACPA as donor 
and acceptor ND -- -- 
HMGS active site substitutions 
C114S ND4 -- -- 
P166A 88.1 ± 0.3 -- -- 
S167A 95.5 ± 0.3 -- -- 
ACPD/HMGS interface substitutions 
ACPD    
R42A 95.7 ± 0.2 -- -- 
HMGS    
R33A ND 6.9 ± 0.7 8 ± 2 
R33D 2 ± 3 29 ± 3 25 ± 3 
D214A 86 ± 8 10.9 ± 0.9 9 ± 2 
D214R 45 ± 4 17 ± 5 11 ± 3 
D222A 27 ± 1 28 ± 2 1.5 ± 0.6 
D222R 17 ± 1 34 ± 2 5 ± 1 
E225A 55 ± 3 90 ± 4 -- 
E225R 8 ± 1 68 ± 5 12 ± 1 
R266A 56 ± 1 110 ± 10 17 ± 2 
R266E 26 ± 1 180 ± 10 17 ± 5 
 
1 Conversion of equimolar acetyl-ACPD and acetoacetyl-ACPA to HMG-ACPA in a 10 minute reaction at 25 
°C. Each value corresponds to the average of 3 measurements. 
2 Affinities were measured by fluorescence polarization using BoDIPY-tagged ACPD. Each value 
corresponds to the average of 3 measurements. 
3 All crystal structures were of the HMGSAAA variant (K343A/Q344A/Q346A). Cys114 is the catalytic 
nucleophile. 
4 No product detected. 
5 In each reaction, either ACPD or ACPA was loaded with both acyl substrates, and equimolar quantities of 





Figure 2.3 Sample HMGS activity data.  Ppant ejection mass spectra of the ACPA 
elution of an HMGS reaction mix. Ion counts were recorded for the acetoacetyl 
(calculated m/z=345.15) and HMG (calculated m/z=405.17) peaks.  See Table 2.2 for 
total ion counts for each species.  
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Table 2.2 Conversion of acetoacetyl-ACPA to HMG-ACPA evaluated by pant 
ejection 
 
 Acetoacetyl (345.15)1 HMG (405.17) Conversion to product (%) 
Wild type 1091.332 5258.49 82.8 
R33A 6255.19 0 0 
D214A 870.19 3527.54 80.2 
D222A 7059.05 2753.29 28.1 
E225A 2997.98 3324.05 52.6 
R266A 3447.38 4178.93 54.8 
 
1Predicted masses for each species are given in parentheses. 
2EIC for spectra in Figure 2.3. One of three replicate experiments for each mutant is shown. Conversion 
to product was calculated as HMG/(HMG+Acetoacetyl) and averaged for the three trials. Error estimates 




Table 2.3 HMGS-dependent de-acetylation of acetyl-ACPD 
 
Sample % Acetyl-ACP 
acetyl-ACPD (no incubation) 87 
acetyl-ACPD (18-hr incubation, no enzyme) 88 ± 4 
acetyl-ACPD (18-hr incubation with HMGSWT) 13 ± 10 
acetyl-ACPD (18-hr incubation with HMGSC114S) 86 ± 0.3 
 
Acetyl-ACPD was evaluated by mass spec Ppant ejection. Values given are the percent 
of total ion counts for ejected acetyl-Ppant among all ejected Ppant species. Incubations 
were at 20 °C in a buffer of 1X MMT (Qiagen) pH 6.5, 20 mM (NH4)2SO4. HMGS was 
present at a 1:10 ratio to ACPD. Under the conditions of the experiment, wild type 
HMGS removed the acetyl group from ACPD by the, but the catalytic variant HMGS 




HMGS structure. A triple alanine HMGS variant (K344A/Q345A/Q347A, 
HMGSAAA) was used for all crystal structures and had catalytic activity indistinguishable 
from the wild type (Table 2.1). The 2.1-Å crystal structure in space group P3121 (Table 
2.4, Figure 2.4) was solved by molecular replacement. HMGS is dimeric in solution and 
in the crystal structure, where the asymmetric unit consists of one subunit (Figure 2.5). 
The catalytic amino acids Glu82, Cys114, and His250 (Fig 2.6 A) are identically 
positioned in HMGS and HMGCS, and the overall folds are similar (RMSD of 2.03 Å for 
368 Cα atoms). Striking differences occur at the active site entrance and the dimer 
interface. A disordered loop (HMGS residues 149-163) near the active site encompases 
a conserved insertion in HMGS (residues 155-164) relative to HMGCS. (Figure 2.7). An 
adjacent loop at the subunit interface (residues 203-210) has a different conformation 
than the analogous loop in HMGCS. The HMGS 203-210 loop forms hydrophobic 
contacts with the partner subunit that involve several residues conserved among HMGS 
but not HMGCS.  
ACPD/HMGS complex. We tested the ACP selectivity of the curacin A HMGS in 
experiments where acyl groups were mismatched with ACPD or ACPA (Table 2.1, Figure 
2.3). ACPA was not a surrogate acetyl donor, as we detected no conversion of acetyl-
ACPA + acetoacetyl-ACPA to HMG-ACPA. In contrast, ACPD was a weak surrogate 
acceptor with threefold-reduced conversion of acetyl-ACPD + acetoacetyl-ACPD to 
HMG-ACPD relative to the natural partners. Thus, HMGS had greater selectivity for the 
donor ACP than for the acceptor. To investigate the structural basis of ACP selectivity, 














































































Table 2.4 crystallographic data collection and refinem
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Figure 2.4 Ramachandran analysis of the HMGS structure. 
MolProbity Ramachandran analysis
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Figure 2.5 CurD HMGS structure. Within the dimer, the right-hand subunit is colored 
by sequence from the blue N-terminus to the red C-terminus. Key residues are shown in 
ball-and-stick on the gray left monomer, including the catalytic Cys114, Glu82 and 
His250. Phe148 and Ala164 are the boundaries of the 15-residue disordered loop at the 
active site entrance. The basic side chain of Arg33 interacts with the Ppant phosphate 
and is conserved in HMGCS sequences. A dotted line denotes the disordered loop 










Figure 2.6 Electron density for holo-ACPD-HMGS. Key residues (ball-&-stick) were 
omitted, and models were refined in phenix.refine with simulated annealing. SA-omit 
density is contoured at 3.0σ in green (A-H) and at 1.5σ in pale green (D,F). HMGS 
residues are in cyan, ACPD in orange, and Ppant in yellow in each panal: Α. Catalytic 
HMGS residues. B. Ppant. C-G. Ionic contacts (Figure 2.7) H. Nonpolar contacts (Figure 





Figure 2.7 Alignment of HMGS and HMGCS sequences. Alignments were generated 
using Clustal Omega60 and analyzed in Jalview61. The boxed sequences, identified by 
protein name, are for the β-branching HMGS and the bottom sequences are for the 
primary metabolism HMGCS, identified by species of origin. Important residues are 
numbered by the CurD HMGS sequence. Ppant interacting residues are identified in 
yellow, catalytic residues in blue, thiol pocket residues in green, and ACPD interacting 
residues in red. Species of origin and accession codes for HMGS sequences are as 
follows: CurD from Moorea producens, Q6DNE9; PksG from Bacillus subtilis, P40830; 
MupH from Pseudomonas fluorescens, Q8RL63; TaC from Myxococcus xanthus, 
Q1D5E5; TaF from Myxococcus xanthus, Q1D5E8; BryR from Ca. Endobugula sertula, 
A2CLL9. Accession codes for HMGCS sequences: Enterococcus faecalis, Q9FD71; 
Staphylococcus aureus, Q9FD87; Brassica juncea, Q9M6U3; Homo sapiens, Q01581.  
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 The HMGS active site entrance and surrounding surface were unhindered by 
crystal contacts, and we captured complexes of HMGS with apo-ACPD, holo-ACPD, and 
acetyl-ACPD by cocrystallization (Figure 2.8-2.10, Table 2.4). The ACPD was well 
ordered at the HMGS active site entrance, made no lattice contacts, and contacted 
neither the partner subunit of the HMGS dimer nor its bound ACPD. The holo-ACPD 
Ppant had clear electron density in the active site (Figure 2.11, 2.6 B) yet formed only a 
few interactions, including the phosphate to HMGS Arg33 and ACPD Arg42, which was 
also salt-bridged to HMGS Asp214 (Figure 2.8). The Ppant-Arg42-Asp214 network is 
specific to ACPD-HMGS pairs (Figure 2.7, 2.12), but the Arg33-Ppant interaction also 
occurred in HMGCS-CoA complexes53,55. Ppant binding induced ordering of amino acids 
159-163 in the HMGS disordered loop, forming a 310 helix with hydrogen bonds of 
Phe163 and Ser167 to the Ppant (Figure 2.8). The Ppant thiol occupies a relatively 
hydrophobic “thiol pocket” (conserved amino acids Ser216, Leu217, Tyr220, Pro252, 
Met256 and Tyr326) and is hydrogen bonded to the Ser216 hydroxy group (Figure 2.8). 
An extensive network of hydrogen bonds involving Ser216, Tyr220, Tyr326 and 
conserved Asp200 maintains the structure of the thiol pocket.  
In the holo-ACPD/HMGS structure, the Ppant and Cys114 thiol groups are too far 
apart (7.9 Å) for the acetyl-transfer step of HMGS catalysis (Figure 2.11). This “distal” 
Ppant position was also occupied in crystals grown from acetyl-ACPD + HMGS, with no 
density for an acetyl at either the Ppant or Cys114 (Figure 2.11, Table 2.4). The acetyl 
group of acetyl-ACPD was apparently transferred to Cys114 and subsequently 
hydrolyzed during crystallization (2-3 days) (Table 2.3). We propose that the distal 
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Ppant position represents a post acetyl-transfer state. Nonproductive loss of the acetyl-




Figure 2.8 HMGS interaction with the donor ACP. A. ACPD (orange) / HMGS (cyan) 
complex. Ppant (yellow) and catalytic residues shown in ball-and-stick form. B. Ppant in 
the HMGS active site. Dashed lines represent hydrogen bonds (yellow) and the long 
separation of Ppant and Cys114 thiol groups (black). C. Stereo view of charged 
contacts in the HMGS - ACPD interface. D. Stereo view of hydrophobic contacts 
between ACPD and HMGS. HMGS helices are numbered as in Figure 2.5, and ACPD 




Figure 2.9 Ramachandran analysis of apo-ACPD/HMGS complex structure. 
  
MolProbity Ramachandran analysis
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Figure 2.10 Ramachandran analysis of holo-ACPD/HMGS complex structure. 
 
MolProbity Ramachandran analysis
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Figure 2.11 Acetylation-dependent position of Ppant. Panels show Fo-Fc omit 
density (3σ, Ser-Ppant omitted, green) for structures of ACPD-HMGS in different 
biochemical states crystallized in identical conditions. A. Holo-ACPD and HMGSWT. 
White box indicates field of view for B and C. B. Acetyl-ACPD and HMGSWT, showing 
that the acetyl group has been lost. C. Holo-ACPD and HMGSC114S. D. Acetyl-ACPD and 
HMGSC114S. Anomalous difference density (3σ, magenta) indicates that S is present in 
both terminal densities for the Ppant and also shows the Ppant P atom. Atoms are 




Figure 2.12 Alignment of ACPD and ACPA sequences. The alignment was generated 
using Clustal Omega60 and analyzed in Jalview61. Boxed sequences are for ACPD and 
below for ACPA. Important residues are numbered by the CurB ACPD sequence.  The 
positions of hydrophobic side chains that are conserved aliphatics in ACPD and aromatic 
in ACPA are indicated by arrows below the alignment (see also Figure 2.14). Species of 
origin and accession codes for HMGS sequences are as follows: CurB and CurA from 
Moorea producens 3L (F4Y434, F4Y435); MacpC and MmpA3_ACPs from 
Pseudomonas fluorescens (Q8RL65, Q8RL76); AcpK and PksL from Bacillus subtilis 
(Q7PC63, Q05470); TaB, TaE, and Ta1 ACPs from Myxococcus xanthus (Q9XB07, 




To trap an acetyl-ACPD complex, we co-crystallized the inactive HMGSC114S with 
acetyl-ACPD (Figure 2.13), resulting in multiple positions for the Ppant terminus (Figure 
2.11), including the previously identified distal holo-Ppant position, again lacking density 
for an acetyl group. A second position was interpreted from a new strong density (15 σ) 
near Ser114 that could represent acetyl-Ppant (Figure 2.11). Two experiments validated 
the interpretation of the second “proximal” acetyl-Ppant position, as its density was 
discontinuous with the rest of the Ppant. We solved the structure of holo-
ACPD/HMGSC114S, yielding density in the distal Ppant position and no density in the 
Ser114-proximal position, establishing that the new density was not due to the C114S 
substitution (Figure 2.11, Table 2.4). To distinguish whether the density near Ser114 
was due to free acetate or the acetyl-Ppant terminus, we used anomalous scattering to 
identify atomic positions of S atoms. Data were recorded at an X-ray energy of 7.0 keV 
from acetyl-ACPD/HMGSC114S co-crystals, yielding anomalous difference electron 
density for the Ppant S in both the distal site and at the site proximal to Ser114 (Figure 
2.11, Table 2.4). A similar experiment with HMGSC114S crystals (no ACPD) lacked 
anomalous difference electron density near Ser114. Thus, we conclude that during 
crystallization some of the acetyl-ACPD hydrolyzed spontaneously, and the remaining 
acetyl-Ppant was adjacent to the nucleophilic side chain (C114S), defining a pre-acetyl-




Figure 2.13 Ramachandran analysis of acetyl-ACPD/HMGS complex structure. 
MolProbity Ramachandran analysis
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ACPD/HMGS interface. The interacting surfaces of ACPD and HMGS are 
complementary in shape and charge (Figure 2.8, 2.14). The primary contact is between 
the N-terminal half of HMGS helix α8 (Figure 2.8) and an ACPD cleft between the Ppant-
Ser39 and helix III. On the ACPD surface, conserved basic residues form a strongly 
electropositive region, which is separated from an electronegative region by a 
hydrophobic stripe (Figure 2.14). We compared the surface features of other ACPs in 
complexes with cognate enzymes37,63–67 to ACPD (Figure 2.14). Positive and negative 
surface regions are typical of PKS ACPs (Figure 2.14 B-E) whereas fatty acid synthase 
(FAS) ACPs are highly electronegative (Figure 2.14 F-I). Among PKS ACPs, ACPD has 
two distinctive features: a strongly electropositive region and a cleft that is 
complementary to a conserved hydrophobic patch (Figure 2.8) (Leu217, Leu218) on the 
outer surface of HMGS helix α8. The analogous surface of the HMGCS helix is polar. 
We evaluated several salt bridges in the ACPD-HMGS interface by mutagenesis 
and, for each variant, measured HMGS activity and ACPD affinity (Table 2.1). Each of 
the HMGS charged residues (Arg33, Asp214, Asp222, Glu225, Arg266) was substituted 
with alanine and an oppositely charged amino acid. Affinities were measured by 
fluorescence anisotropy with a fluorophore-conjugated ACPD (Figure 2.15). The HMGS 
Kd was 1.1 μM for apo-ACPD and 0.5 μM for holo-ACPD, indicating significant protein-
protein affinity and a twofold contribution from the Ppant cofactor. Asp222, Glu225, and 
Arg266 are involved in only the protein-protein interface and do not contact the Ppant 
(Figure 2.8). Correspondingly, substitutions to these residues had a greater impact on 
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the affinity of apo-ACPD than holo-ACPD. Substitutions to phosphate-interacting Arg33 
and Asp214 resulted in equal affinities for holo and apo-ACPD. 
 
 
Figure 2.14 Electrostatic surface potentials and interacting surfaces for HMGS 
and selected ACPs. For ACPs from structures of enzyme complexes, the black outline 
delineates the molecular surface within 5 Å of any atom in the interacting enzyme and 
the yellow star denotes the site of Ppant attachment. A. CurD HMGS (complex with 
CurB ACPD). B. CurB holo-ACPD (complex with CurD HMGS). C. CurA ACPA (2LIW 37, 
RMSD 2.2 Å). D. DEBS module 2 ACP (2JU2 63, RMSD 2.7 Å). E. VinL ACP (5CZD, 68, 
complex with VinK Acyltransferase, RMSD 2.6 Å). F. E. coli AcpP (complex with E. coli 
FabA dehydratase, 4KEH 64, RMSD 2.1 Å). G. E. coli AcpP  (complex with E. coli LpxD, 
4IHG 65,RMSD 3.5 Å). H. B. subtilis ACP (complex with B. subtilis ACP synthase, 1F80 
67, RMSD = 2.2 Å). I. R. communis ACP (complex with R. communis ACP desaturase, 
2XZ1 66, RMSD 1.7). Molecular surfaces are colored by electrostatic potential (±5 kT/e, 
blue electropositive, red electronegative) 69. RMSD values are from Cα superposition 




Figure 2.15 Affinity of ACPD for wild type and variant HMGS. Fluorescence 
anisotropy of BODIPY-tagged ACPD was recorded as a function of HMGS 
concentration. For each HMGS variant, binding curves are shown for apo-ACPD (left) 
and holo-ACPD (right). Data were recorded and analyzed with Graphpad Prism70. Data 




 We evaluated several salt bridges in the ACPD-HMGS interface by mutagenesis 
and, for each variant, measured HMGS activity and ACPD affinity (Table 2.1). Each of 
the HMGS charged residues (Arg33, Asp214, Asp222, Glu225, Arg266) was substituted 
with alanine and an oppositely charged amino acid. Affinities were measured by 
fluorescence anisotropy with a fluorophore-conjugated ACPD. The HMGS Kd was 1.1 
μM for apo-ACPD and 0.5 μM for holo-ACPD, indicating significant protein-protein affinity 
and a twofold contribution from the Ppant cofactor. Asp222, Glu225, and Arg266 are 
involved in only the protein-protein interface and do not contact the Ppant (Figure 2.8). 
Correspondingly, substitutions to these residues had a greater impact on the affinity of 
apo-ACPD than holo-ACPD. Substitutions to phosphate-interacting Arg33 and Asp214 
resulted in equal affinities for holo and apo-ACPD. 
 The effect of the HMGS substitutions on activity did not show a clear pattern for 
Ppant-interacting and protein-protein contact residues. The Arg33 variants had little or 
no activity, suggesting that the Arg33 may orient Ppant in the active site. In contrast, 
substitutions to Asp214 did not significantly affect activity. To further test the importance 
of HMGS-Ppant interactions, we made alanine substitutions to Ser167 and to Pro166, 
which we hypothesized would increase helicity of Phe163 and prevent its carbonyl from 
interacting with Ppant. Despite the conservation of these residues, both variants had 
similar activity to wild-type HMGS, suggesting their interaction with Ppant may be 
unimportant for the acetylation step of the HMGS mechanism. 
 Substitutions to charged side chains in the protein-protein interface caused 
modest reductions in HMGS activity that were not correlated with changes in affinity, 
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indicating that HMGS-ACPD affinity is not limiting in the assay conditions. At each 
position, the effect of the charge-reversal substitution was more deleterious to HMGS 
activity (3- to 10-fold) than was the Ala substitution (3-fold or less). The greatest effects 
occurred for charge-reversal substitutions at Asp222 (5-fold) and Glu225 (10-fold). 
Located on adjacent turns of helix α8 (Figure 2.8), Glu225 forms a salt bridge with ACPD 
Arg59, and the Asp222 carboxylate “caps” ACPD helix III, which is an atypical 310 helix 
in an unusual position in the ACP (Figure 2.8). Thus, Asp222 and Glu225 may help 
orient ACPD on HMGS, or may be anti-selective for ACPA at this position.  
Discussion 
HMGS catalyzes the key reaction of polyketide β-branching, a critical process for 
chemical diversification in this important class of natural products. The β-branching 
HMGS of the curacin A biosynthetic pathway exhibits a remarkable selectivity for its 
donor (ACPD) and acceptor (ACPA) substrates (Table 2.1), like related enzymes24,20,25. 
This selectivity enables proper sequencing of substrates during catalysis and prevents 
aberrant β-branching by mis-association with other ACPs within the PKS pathway. 
The ACPD-HMGS structures capture the ACPD Ppant in pre- and post-acetyl 
transfer positions. In the Cys-distal, post-acetyl-transfer position, the Ppant thiol was 
bound deep within a conserved thiol pocket that occludes the acetyl group, whereas the 
poorly ordered acetyl-Ppant was in the Cys-proximal position (captured in the Ser114 
variant). This contrasts with structures of HMGCS-CoA complexes53–55,57,71 where, in all 
cases supported by electron density, the Ppant was bound near the distal site with the 
thiol directed into the active site cavity regardless of its acylation state. Nevertheless, 
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the HMGS and HMGCS active sites are nearly identical, and thus we infer that HMGS 
and HMGCS have identical stereochemical outcome, generating only S-HMG products. 
A major motivation for our study was to investigate how HMGS distinguishes the 
two ACP substrates. The structures of the ACPD-HMGS complexes indicate that HMGS 
excludes ACPA from the ACPD site, consistent with the inability of ACPA to act as an 
acetyl donor in the reaction (Table 2.1). ACPD has a surface shape that is 
complementary to the HMGS surface and that differs from surfaces of ACPA and other 
ACPs. A hydrophobic cleft, due to the unique position of ACPD helix III, is matched with 
a hydrophobic ridge on the surface of HMGS helix α8 (amino acids 213-234) and is 
flanked by polar contacts, including Asp222 on helix α8 with backbone amides at the N-
terminus of ACPD helix III. ACPA has no hydrophobic surface cleft because helix III is in 
a more typical position. None of the salt bridges between amino acids in ACPD and 
HMGS was critical for binding or catalysis when tested by single-residue mutagenesis 
(Table 2.1), leading us to conclude that surface complementarity is the dominant factor 
in the HMGS-ACPD interface.  
ACPs from PKS pathways37,45,63,68 have distinctive surface charge distributions 
compared to FAS ACPs64–67, but in both systems the ACP helix II-III surface interacts 
with enzymes (Figure 2.14). The PKS ACPs have regions of positive surface potential 
near the point of contact with their cognate enzymes, whereas the analogous surface of 
the FAS ACPs is negatively charged. The distinctive pattern of negative/neutral/positive 
surface potential of β-branching ACPs (ACPD, curacin A and mupirocin ACPAs) may 
contribute to HMGS selectivity against the ACPs within PKS modules where the surface 
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potential pattern differs (Figure 2.14). The unusual ACPD helix III, accompanying surface 
cleft, and striking electrostatics specialize ACPD for selective interaction with only the β-
branching HMGS and KSDC enzymes (Figure 2.2). In contrast, ACPA shuttles substrates 
to seven enzymes in the curacin A pathway, including β-branching and module 
enzymes, necessitating a more promiscuous ACP-surface for enzyme interaction. 
The ACPD-HMGS interface provides clues about the selectivity of β-branching in 
the myxovirescin pathway, which has two ACPD/HMGS pairs (TaB/TaC and TaE/TaF). 
TaB/TaC generates a methyl branch, while the unusual TaE/TaF pair installs an ethyl 
branch72. Each HMGS (TaC and TaF) is highly selective for its donor ACP (acetyl-TaB 
and propionyl-TaE, respectively) and does not react with the non-cognate ACPD20. We 
generated homology models of TaB and TaE, based on the CurB ACPD structure and of 
TaC and TaF based on CurD HMGS. Some ACPD/HMGS interactions are recapitulated 
in both myxovirescin β-branching reactions, and the TaB/TaC pair retains most of the 
interactions of CurB/CurD. However, at other interacting positions, complementary 
sequence changes in TaE ACPD and TaF HMGS would interfere with binding to the 
non-cognate partner. For example, TaE Lys57 pairs well with TaF Glu267, but not with 
TaC Lys267; and TaB Arg59 pairs well with TaC Glu225, but not with TaE Lys225. 
 Catalytic fidelity in a reaction with distinct donor and acceptor substrates is a 
common problem for HMGS and two homologs: the HMGCS of primary metabolism and 
the KS domain of modular PKS pathways. The enzymes employ different mechanisms 
of substrate selectivity, although they have analogous active site entrances for their acyl 
donor substrates. HMGCS has a single binding site for the acetyl-donor and 
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acetoacetyl-acceptor CoAs54,71, but excludes the acetyl-CoA donor following acetyl 
transfer to the enzyme31. Like HMGS, the PKS KS domain has two ACP substrates, but 
uses separate active site entrances for the donor (upstream module) and acceptor 
(intra-module)8. The PKS KS restricts access of each ACP to the appropriate entrance 
by the module architecture and ACP tethering via fusion or interaction of docking 
domains8,12,14,43,44. In contrast, HMGS interacts with two ACPs in trans, and robust 
binding of ACPD (Kd 0.5 µM for holo-ACPD) is not acyl-group dependent. Nor is the 
ACPD docking site on HMGS analogous to either of the ACP-KS docking sites observed 
in cryo-EM maps of a PKS module8. We find no evidence of a second active site 
entrance in the HMGS structure (for example, poorly ordered loops that could expose 
the active site, as in the KS8,13,44,73). We conclude that ACPA and ACPD insert acyl-
Ppant through the same active site entrance, as do the donor and acceptor-CoAs of 
HMGCS, but that the ACPs interact with different regions of the HMGS surface.  
The HMGS flexible loop, which does not exist in either HMGCS or KS, is a prime 
candidate for ACPA interaction, as it is adjacent to the active site. A critical question is 
whether the ACPs engage HMGS simultaneously or sequentially. The affinity of HMGS 
for ACPD is tenfold greater than a native docking domain pair (Kd 0.5 µM vs. 5-25 
µM)43,44. HMGS has lower affinity for ACPA than for ACPD, based on the Kd of 150-200 
µM for the bryostatin HMGS and its cognate ACPA25. Cooperativity may enhance weak 
intrinsic ACPA binding to HMGS because β-branching cassettes typically encode 
tandem ACPAs, for example the CurA tandem ACPA tridomain of nearly identical 
sequences with an additional dimerization element at the C-terminus49. In the HMGS 
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dimer, the two active site entrances are separated by 40-50 Å, a distance that may be 
spanned by tandem or dimeric ACPs. However, the high activity of HMGS under assay 
conditions with equal concentrations of ACPD and single-domain ACPA implies that 
HMGS may either promote dissociation of ACPD, following acetyl transfer to Cys114, or 
simultaneously engage acetoacetyl-ACPA to prevent formation of a dead-end complex. 
Thus, interaction with acetoacetyl-ACPA could trigger both catalytic and conformational 
events, including rearrangement of the flexible loop to disengage ACPD or to widen the 
active site entrance to accommodate two Ppant cofactors. The possibilities are not 
resolved by the present structures. 
In conclusion, the first structure of an HMG synthase involved in polyketide 
biosynthesis reveals features that distinguish HMGS from its primary metabolism 
homolog and allow it to interact selectively with its cognate ACPs. Analysis of the 
HMGS-ACPD interface provides insight into HMGS selectivity in other pathways, 
including those with multiple β-branching functions. The HMGS structures with acetyl 
and holo-ACPD provide a unique view of the molecular interactions between a PKS 
enzyme and its substrate, revealing the mechanism by which HMGS prevents its 
substrate from adopting a non-productive orientation in the active site. Finally, the 
unusual position of helix III in ACPD is a new structural motif in acyl carrier proteins that 






Protein expression and purification 
 Our expression plasmid for the curacin A HMGS (pHMGScur) was generated by 
amplifying the CurD gene from the pLM5452 cosmid (Table 2.5) and inserting it into 
pMCSG774 by ligation independent cloning (LIC). The curB gene encoding ACPD was 
amplified from a pET28b construct74 (Table 2.5) and inserted by LIC into pMCSG7 
(pACPdcur). pHMGScur was coexpressed with pGro775 (Takara) in E. coli BL21 (DE3) 
cells. pACPDcur was coexpressed with pRARE-CDF44 in E. coli BL21 (DE3) (for 
apo/acyl-loaded proteins) or Bap176 (for holo proteins) cells containing pRARE. E. coli 
BL21 (DE3) cells were transformed with pLG00349 for expression of CurA ACP II, the 
second of the CurA tandem ACPA tridomain. Transformed bacteria were grown with 100 
mg/L ampicillin and 35 mg/L chloramphenicol for HMGS, 100 mg/L ampicillin and 50 
mg/L spectinomycin for ACPD, or 50 mg/L kanamycin for ACPA at 37 °C in TB to an 
OD600 of 1. GroEL/ES chaperone expression was induced with 2 g/L arabinose for 
HMGS cultures at an OD600 of 0.3. Cells were cooled to 20 °C and target gene 
expression was induced with 200 μM IPTG. After 18 hr of expression, cells were 
harvested and stored at -20 °C. Cell pellets were resuspended in buffer A (300 mM 
NaCl, 50 mM tris pH 7.5, 20 mM imidazole pH 8.0, and 10% glycerol for ACPs; 50 mM 
(NH4)2SO4, 50 mM HEPES pH 7.0, 20 mM imidazole pH 8.0, and 10% glycerol for 
HMGS). Cell suspensions were treated with 1 mg/mL lysozyme (Sigma), 2 mM MgCl2, 
and 20 U/mL Pierce universal nuclease for 30 minutes at room temperature (RT), then 
cooled on ice. Cells were lysed by sonication and cleared by centrifugation. Each 
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protein was purified by immobilized metal affinity chromatography on a 5 mL His Trap 
column (GE Healthcare) with a 50 mL gradient from 20 mM (buffer A) to 400 mM 
imidazole (buffer B), followed by size exclusion chromatography (SEC). HMGS was 
purified on a Superdex S200 column in 50 mM (NH4)2SO4, 20 mM HEPES pH 7.0, and 
10% glycerol (HMGS buffer C), and ACPs on a Superdex S75 column in 150 mM NaCl, 
20 mM Tris pH 7.5, and 10% glycerol (ACP buffer C). Proteins were concentrated to 
~10 mg/mL, flash cooled in liquid N2 and stored at -80 °C. 
Site directed mutagenesis 
Constructs encoding HMGS and ACPD variants were generated by site directed 
mutagenesis (SDM) on pHMGScur and pACPDcur by PCR with overlapping primers 
(Table 2.5). SDM PCR components were 2 ng/μL of pHMGScur or pACPDcur, 200 nM 
sense and 200 nM antisense primer, 0.05 U/μL Pfu Turbo polymerase (Agilent), and 
250 nM dNTPs, in 1X Pfu buffer (Agilent). After PCR, 0.4 U/μL DpnI (NEB) was added 
to each reaction and incubated for 2 hr at 37 °C. 2μL of this mixture was transformed 
into E. coli XL-1 Blue cells. Mutant expression constructs were purified by miniprep kit 
(Qiagen), and the mutations were verified by Sanger sequencing. 
Table 2.5. Primers for cloning and mutagenesis of CurD HMGS and CurB ACPD. 
Ligation independent cloning (LIC) overhangs are bolded. 
 
Cloning Primers 









Mutation Sense Primer Antisense Primer 










HMGS: P166A ccagcaccactactggcttcagcaaaagaccaatc 
gattggtcttttgctgaagccagtagt
ggtgctgg 
HMGS: S167A ggctccagcaccactagcgggttcagcaaaagac 
gtcttttgctgaacccgctagtggtgc
tggagcc 
HMGS: R33A catcattagattgtcaaaggcggagatatccaactgacgc 
gcgtcagttggatatctccgcctttga
caatctaatgatg 
HMGS: D214A aagaaagcaaggataaggcggcatctcctgcttct 
agaagcaggagatgccgccttatcctt
gctttctt 
HMGS: D222A taggcattttcgcaacaggctaggtaagaaagcaagg 
ccttgctttcttacctagcctgttgcg
aaaatgccta 
HMGS: E225A taatgtcggtaggcatttgcgcaacagtctaggtaag 
cttacctagactgttgcgcaaatgcct
accgacatta 
HMGS: R266A ggtttagctcttttcaacctagccatcatatttctatgagcgcc 
ggcgctcatagaaatatgatggctagg
ttgaaaagagctaaacc 
HMGS: R33D tcatcattagattgtcaaagtcggagatatccaactgacgcg 
cgcgtcagttggatatctccgactttg
acaatctaatgatga 
HMGS: D214R gtaagaaagcaaggataagcgggcatctcctgcttctgaa 
ttcagaagcaggagatgcccgcttatc
cttgctttcttac 
HMGS: D222R ggcattttcgcaacagcgtaggtaagaaagcaaggataagtc 
gacttatccttgctttcttacctacgc
tgttgcgaaaatgcc 
HMGS: E225R ttgataatgtcggtaggcatttctgcaacagtctaggtaagaaagc 
gctttcttacctagactgttgcagaaa
tgcctaccgacattatcaa 






















ACPs in the apo state were loaded in vitro with acyl-Ppants by incubation with 
Streptomyces verticillus phosphopantetheinyl transferase77 (SVP), in a 10:1 ratio of 
ACP:SVP, and acyl-CoA, in a 1:10 ratio of ACP:CoA, in a buffer of 10 mM MgCl2, 50 
mM Tris pH 7.5 for 3 hr at 30 °C. Acylated ACPs were purified from loading reaction 
components by SEC on a Superdex S75 column equilibrated with ACP buffer C. The 
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HMGS assays were performed at 25 °C in a buffer of 20 mM (NH4)2SO4, 20 mM HEPES 
pH 7.0, and 2 mM tris (2-carboxyethyl)phosphine (TCEP) for 10 min, followed by 
quenching with 5% formic acid. The concentrations of assay components were 5 μM 
HMGS, 50 μM acetyl-ACPD, and 50 μM acetoacetyl-ACPA. ACPA was separated from 
other reaction components by HPLC on a Jupiter C4 column with a gradient of 30% to 
95% acetonitrile in 0.1% trifluoroacetic acid (TFA) over 15 min with a flow rate of 0.2 
mL/min. The ACPA peak fraction was stored at -20 °C until mass spectrometry analysis 
by Q-TOF (Agilent) with phosphopantetheine ejection59. Total ion counts for holo, acetyl, 
acetoacetyl, and HMG-loaded Ppant species were recorded (Agilent MassHunter 
software). Reaction progress was calculated by the percent of all ejected Ppant ions 
loaded with HMG and averaged for 3 replicates. 
ACPD Hydrolysis Assay 
 100 μM acetyl-ACPD was incubated 18 hr at 20 °C in a 20 mM (NH4)2SO4 + 1X 
MMT pH 6.5 (Qiagen) with 10 μΜ HMGSWT, 10 μM HMGSC114S, or alone. Samples were 
acidified with 5% formic acid and analyzed by HPLC and MS Ppant ejection as 
described above. An additional 100 μM acetyl-ACPD was analyzed without incubation. 
Percent loading of the ACPD with acetyl was determined using ion counts for acetyl-
Ppant and holo-Ppant species. 
Fluorescence anisotropy binding assay 
 Met1 of CurB ACPD was mutagenized to cysteine. ACPD M1C was reduced for 
15 min at RT with 2 mM TCEP, then incubated with 10-fold excess BODIPY-FL 1-
iodoacetamide (Invitrogen) at room temperature for 3 hr. BODIPY-FL-conjugated ACPD 
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was purified from free BODIPY using a PD-10 column with ACP buffer C, flash frozen, 
and stored at -80 °C. HMGS was dialyzed overnight at 4 °C into 20 mM (NH4)2SO4 and 
20 mM HEPES pH 7.0. 10 serial 2X dilutions of the HMGS stocks were made, then 45 
μL of each of these 11 HMGS samples was mixed with 5 μL of 0.1 nM ACPD-1-BODIPY 
in an opaque 384 well plate. 45 μL buffer was mixed with 5 μL of 0.1 nM ACPD-1-
BODIPY for a control. The plate was incubated at RT for 30 min, then fluorescence 
anisotropy was measured with a λEX of 485 nm and λEM of 525 nm (Figure 2.15). The 
data were fit to A = Afree + (ΔAbound x [HMGS]/ (Kd+[HMGS])) (GraphPad Prism) to 
determine affinities. In cases where ΔAbound, the change in anisotropy when ACPD is 
maximally bound, could not be fit from the data, ΔAbound was held at a constant value as 
determined from the average of trials where it was experimentally measured.  
Crystallization 
Substitutions to HMGS to make it more amenable to crystallization were 
predicted using the surface entropy reduction server78. Using these predictions, a triple 
alanine variant, HMGSAAA, (K344A/Q345A/Q347A) was generated by SDM. HMGSAAA 
was crystallized by hanging-drop vapor diffusion from 1:1 and 2:1 mixtures of protein 
stock (10 mg/mL in HMGS buffer C) and well solution (20 mM (NH4)2SO4, 1X MMT 
buffer pH 6.5 (Qiagen), 6% w/v PEG 8000) at 20 °C. For HMGS/ACPD complex crystals, 
each protein was concentrated to 25 mg/mL then mixed in an HMGS:ACPD ratio of 2:3. 
HMGS/ACPD (apo) co-crystals were obtained with a well solution of 100 mM (NH4)2SO4, 
1X MMT buffer pH 6.5, 2% w/v PEG 8000. HMGS/ACPD (holo) crystallized with a well 
solution of 120 mM (NH4)2SO4, 1X MMT buffer pH 6.5, 10% w/v PEG 8000 at 20 °C. 
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Crystals were cryoprotected in well solution with 25% v/v glycerol prior to flash cooling 
in liquid N2. Crystallization trials using refined conditions and HMGSWT (again 
cocrystallized with a 7:1 molar ratio of ACPD:HMGS) yielded only microcrystals that 
were not suitable for harvesting or diffraction. 
Structure solution and refinement 
Data were collected at the Advanced Photon Source (APS) GM/CA 23ID-D and 
processed with XDS79. Diffraction limits were determined by CC1/2 and I/σI statistics, and 
subsequent calculations were done with the ccp4 suite80. The HMGS structure was 
solved by molecular replacement in phaser81 from an HMG-CoA synthase model55 
(1YSL) that was trimmed with chainsaw82. A 97%-complete initial model was auto-built 
using ARP/wARP83, model refinement was done in refmac584 with TLS85 parameters, 
and real space building with Coot86. Waters were manually added in coot to positive FO-
FC difference density in positions consistent with hydrogen bonding to the protein. 
Waters were removed after refinement if they corresponded to negative difference 
density, had 2Fo-Fc density weaker than 0.6σ, or resulted in clashes. HMGS/ACPD 
complex structure was solved by molecular replacement with the HMGS structure, 
followed by manual building of the ACPD model in Coot and refinement in refmac5 with 
TLS parameters. Despite high B-factors for residues distal from HMGS that had no 
crystal contacts, we found continuous main chain density for residues 1-78 in all 
deposited structures, and density for side chains contacting HMGS was well resolved. 
Subsequent HMGS/ACPD complex structures were solved by rigid body refinement with 
HMGS and ACPD models. To validate the Ppant position in our model of the pre-acetyl 
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transfer complex, we collected data on holo-ACPD/HMGSC114S crystals at 12 keV and 
Friedel-pair data at an X-ray energy of 7 keV on acetyl-ACPD/HMGS (C114S) and 
HMGS (C114S) crystals. Data were processed with XDS, and phased by rigid body 
refinement in refmac5. Following model refinement and addition of waters, sulfur atomic 
positions were identified in an anomalous difference map The peak heights for the holo 
and acetyl thiol positions were 4.0 and 3.7, respectively, and peaks for cysteines and 
methionines ranged from 4.0 to 8.1. Refined models were validated and Ramachandran 
plots were generated by Molprobity87, followed by a final round of building in coot and 
refinement in refmac5. Molecular figures were generated in PyMOL88. 
Homology modeling of myxovirescin HMGS and ACPD 
Homology models of the TaB and TaE ACPDs and of the TaC and TaF HMGSs were 
generated using Modeller89 using sequence alignments by Clustal Omega60 (Figure 2.6 
2.7, 2.12) and our structure of the holo-ACPD/HMGS complex. Models for TaC and TaF 
were aligned to CurD HMGS and models for the TaB and TaE ACPDs were aligned to 












 Modular polyketide synthase (PKS) pathways are enzyme assembly lines that 
process acyl-CoA building blocks to create complex, bioactive small molecules4–6. Each 
module is a set of fused catalytic domains and an acyl carrier protein (ACP) domain, 
which tethers intermediates via a phosphopantetheine arm, shuttles them to each 
enzymatic domain in the module, and passes the intermediate to the next module10. 
Modules include enzymes to extend the polyketide and to make modifications after 
extension, allowing different functional groups to be incorporated into each building 
block of the natural product. Polyketides are an astoundingly diverse group of natural 
products and an important source of pharmaceuticals50. The architecture of PKS 
pathways has attracted interest as a target for engineering, as successfully 
reprogramming the assembly line could allow production of new pharmaceutical 
leads2,3. To this end, biochemically characterizing PKS enzymes that introduce unusual 
functional groups may lead to new enzymatic tools for engineering pathways or as 
reagents for chemoenzymatic synthesis. 
Several modular PKS pathways include enzymes for alkylation of the nascent 
polyketide at a specific intermediate in the assembly line (β-branching)18. This invariably 
occurs after extension by a module with no modification enzymes, which leaves the β-
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carbonyl generated by the ketosynthase extension enzyme intact. β-branches are often 
methyl groups, but also include many unique or rarely-seen substituents in polyketides 
(Figure 1.3). In β-branching, a hydroxymethylglutaryl synthase (HMGS) catalyzes the 
initial aldol addition of an acetyl nucleophile to the β-carbonyl intermediate generated by 
polyketide extension24,25. The HMGS reaction generates a chemical starting point that 
can be tailored to a diverse array of alkyl substituents by the other β-branching 
enzymes18. HMGS is selective for an ACP within the biosynthetic pathway (the acceptor 
ACP, ACPA) that tethers the intermediate subject to branching, and a standalone ACP 
(the donor ACP, ACPD) found with the β-branching enzymes that delivers the donor acyl 
group for branching. Each of these ACPs has distinguishing sequence motifs, and 
HMGS does not react with substrates delivered by CoA or non-branching ACPs24,20,25,90. 
Additionally, HMGS is weakly reactive when ACPD delivers both substrates and 
nonreactive when both are delivered by ACPA90. 
The mechanism by which HMGS catalytically differentiates between substrates 
tethered by each ACP is unknown. HMGS, like many PKS enzymes, was at some point 
poached from a primary metabolism pathway and adapted to polyketide biosynthesis. 
The primary metabolism homolog of HMGS is HMG-CoA synthase (HMGCS), which 
catalyzes the aldol addition of acetyl-CoA to acetoacetyl-CoA (Figure 2.2)30. The 
structure and biochemistry of HMGCS has been extensively characterized. HMGS is 
very similar to HMGCS but has a distinctive structural elements that may play a role in 





Figure 3.1 Structure of conserved structural elements of HMGS. A. Electrostatic 
surface of HMGS and conserved residues. The HMGS surface within 5 Å of ACPD is 
opaque with the rest transparent. Outlined residues are as follows: I, charged residues 
previously studied for interaction with ACPD90; II, previously unstudied conserved 
charged residues; III, conserved residues within the HMGS flexible loop; IV, residues of 
the thiol pocket. B. Surface charged residues (I, II). Green residues correspond to 
region II and the Ppant is shown in yellow, as ordered in the structure of the HMGS-
ACPD complex (5KP7). Arg103, Arg382, and Lys410 extend from the partner subunit of 
the HMGS homodimer. C. HMGS flexible loop (III). Active site residues and those that 
interact with Ppant are colored in cyan, other conserved residues of the flexible loop are 
colored in green. Tyr159, Trp161, and F148 form a π-stack. Leu149 and Arg147 project 
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towards the interior of HMGS with Asp160 exposed on the surface. D. Residues of the 
thiol pocket (IV). Active site residues and residues of the thiol pocket are shown in cyan, 
the Ppant in yellow, and ACPD in orange. The Ppant thiol makes a hydrogen bond to 
Ser216, which in turn interacts with Asp200 and Tyr326. Tyr220 packs against the thiol 
and makes a hydrogen bond to the carbonyl of H250, an essential catalytic residue. 
Leu217 appears to be important for both defining the thiol pocket and making a 
hydrophobic contact with ACPD. 
 
The most prominent of these structural elements is an insertion in HMGS relative 
to HMGCS that corresponds to a flexible loop near the active site entrance. The loop 
itself has several conserved positions (Appendix 3.1), including an “EGGEAL” motif 
(EGGEAI in CurD, residues 152-157), which is disordered in the HMGS structure. 
HMGCS sequences from bacteria include part of the motif but not the full HMGS flexible 
loop, and HMGS that use a propionyl donor group lack the motif entirely. The GGE in 
structures of S. aureus (1TVZ) and E. faecalis (1X9E) HMGCS is ordered and 
corresponds to Ala164 and Phe163 in HMGS, implying a different role for this motif in 
HMGCS and HMGS. The C-terminal end of the flexible loop orders upon holo-ACPD 
binding and forms a helix that makes two hydrogen bonds to the Ppant (Figure 3.1C). 
This helix appears to be further stabilized by a π-stacking interaction between Phe148, 
Trp161, and Tyr159. Tyr159 and Trp161 are part of a conserved 159-EDWSF/Y-163 
motif (Y159 in CurD is usually E159). Though Asp160 in this motif is nearly invariant 
among HMGS (excluding those that use propionyl), it hangs out into space in the HMGS 
structure and has no apparent importance.  
HMGS and HMGCS both contain a hydrophobic pocket in the active site. In 
HMGS, the Ppant thiol of holo-ACPD localizes to this pocket and makes a hydrogen 
bond to Ser216. Positioning of the thiol in the thiol pocket may be incompatible with 
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acetyl transfer due to an 8 Å distance between the holo-Ppant thiol and the catalytic 
cysteine. In contrast, acetyl-Ppant adopts a different conformation that positions the thiol 
near to the cysteine90.Residues pack tightly around the Ppant thiol and could occlude 
acetyl-Ppant from the deepest end of the pocket, preventing the substrate from adopting 
a non-reactive conformation in the active site. In structures of HMGCS with bound CoA, 
the Ppant does not penetrate as deeply into the active site and the thiol angles toward 
the HMGCS cysteine in a catalytic position.  
Finally, the electrostatic landscape surrounding the active site is different in 
HMGS and HMGCS (Figure 3.2). HMGCS has regions of positive charge that interact 
with the 5’ diphosphate and 3’ phosphate of CoA. The surface surrounding the HMGS 
active site has positive and negative areas that are separated by a hydrophobic stripe. 
These regions complement the surface charges of ACPD and include conserved acidic 
and basic residues that make salt bridges to the ACP. These regions may exclude other 




Figure 3.2 Electrostatic comparison of HMGS and HMGCS. A. Curacin A HMGS 
(5KP7)90. B. E.faecalis HMGCS (1YSL)55.  
 
 In this chapter we evaluate the importance of these conserved structural 
elements to HMGS reactivity, with a secondary goal of determining how HMGS 
distinguishes between ACPA and ACPD linked substrates. We observed  a critical 
dependence of HMGS activity on residues within the thiol pocket region, several of 
which also affected ACPD affinity. Apart from a few residues, reductions in ACPA affinity 
were modest. The results provide a groundwork for studying ACP interactions with the 
curacin A HMG, more definitively resolve questions about how ACPs interact with 






Dependence of ACP interactions on surface electrostatics. Based on the 
previous observation that ACPD binding to HMGS was strongly influenced by charge-
charge interactions90, we identified conserved charged residues on the surface of 
HMGS that were not conserved in HMGCS and did not appear to interact with ACPD 
(Figure 3.1B, 3.2).  Most HMGS variants behaved well through purification and were 
assayed for activity, holo-ACPD affinity, and holo-ACPA affinity (Table 3.1). 
Table 3.1 Surface electrostatic substitutions 
 HMGS activity1 (% 
conversion) 
ACPD Kd2 (μM) ACPA Kd2 (μM) 
WT 78.3 ±0.9 0.2 ± 0.1 8 ± 2 
D30A 50 ± 1 16 ± 11 5 ± 2 
R103A 47 ± 2 7 ± 3 4 ± 2 
K410A 71.9 ± 0.9 1 ± 0.5 8 ± 2 
R262A 27 ± 8 0.8 ± 0.3 33 ± 17 
R33A N.D.3,4 8 ± 25 25  ± 13 
R33D 2 ± 33 25 ± 35 N.B.6 
D214A 86 ± 83 9 ± 25 10 ± 2 
D214R7 45 ± 43 11 ± 35 -- 
E225A8 55 ± 33 -- -- 
E225R 8 ± 13 12 ± 15 11 ± 3 
D222A 27 ± 13 1.5 ± 0.65 15 ± 7 
R266A 26 ± 13 17 ± 55 19 ± 13 
 
1Conversion of equimolar acetyl-ACPD and acetoacetyl-ACPA to HMG-ACPA in 7 min at 25 °C, averaged 
for 3 reactions. 
2Affinity was measured by fluorescence polarization using Bodipy-FL conjugated ACPs. 
3Previously published data90. Assay conditions were slightly different. WT HMGS converted 82.8 ± 0.3 % 
of substrate to HMG-ACPA. 
4 No product detected in activity assay. 
5Previously published data90. Buffer for affinity assay was 20 μM (NH4)2SO4, 20 μM HEPES pH 7.0. 
Measured HMGS-ACPD affinity was 0.5 ± 0.2 μM. 
6No binding detected by fluorescence anisotropy. See Figure 3.5 for binding data. 
7HMGSD214R was unstable in low salt buffer for the fluorescence anisotropy experiment and reliable 
binding data for ACPA interaction could not be obtained. 
8HMGSE225A was unstable during protein production/purification and only low amounts of stable protein 
could be obtained for activity assays. 
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D30A, R103A, K410A, and R262A substitutions did not significantly impact HMGS 
activity or ACPA affinity. HMGSD30A and HMGSR103A had 80-fold and 35-fold decreases 
in affinity for ACPD, although they do not directly contact ACPD. As previously 
observed90, decreases in ACP affinity are not correlated with loss of activity. HMGSR33A 
and HMGSR33D are similarly inactive, yet R33D has a larger impact on ACPA and ACPD 
affinity, with the ACPA affinity too weak to be measured. HMGSR262A had 4-fold reduced 
activity, signifying it may be important to the ACPA interface.  
We also investigated the possibility of competition between ACPD and ACPA 
binding using our FP assay (Figure 3.3). We mixed 2 -16 μM unlabeled holo-ACPD with 
8.8 μM HMGS and 20 nM fluorescent ACPA. At concentrations of unlabeled ACPD 
greater than ~8 μM, where most HMGS would be bound by unlabeled ACPD, we 
observed reduction in fluorescence anisotropy of ACPA, as would be predicted if ACPD 
and ACPA binding to HMGS were mutually exclusive. As a positive control, we repeated 
the experiment with unlabeled holo-ACPA (5-80 μM) and observed a similar reduction in 
ACPA fluorescence anisotropy. Thus the ACPA binding site on HMGS may overlap with 
that of ACPD, at least in part, but ACPA does not show the same strong dependence on 




Figure 3.3 ACP competitive binding. Fluorescence anisotropy data for fluorescent 
ACPA binding to HMGS is shown. Various concentrations of unlabeled ACPA or ACPD 
were mixed with a constant 8.8 μM HMGS and 20 nm fluorescent ACPA. Dotted lines 
signify fluorescence anisotropy for ACPA in the absence of HMGS (0.16 ± 0.01). At each 
concentration, the fraction of HMGS bound by the unlabeled ACP was calculated, based 
on the measued ACPA Kd of 8 μM, and is shown as a faded background. 
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Importance of the active site thiol pocket to HMGS activity. We observed an 
extensive hydrogen-bonding network in the HMGS active site, which included residues 
previously identified as important to HMGS and HMGCS catalysis, as well as residues 
that interact with the ACPD Ppant thiol. Our hypothesis for the role of this pocket during 
donor-acyl transfer was that it sterically occluded acetyl-Ppant before 
transthioesterification, preventing the substrate from adopting a non-catalytic pose. 
Lacking a structure of the ACPA-HMGS complex, we additionally sought to determine 
whether these conserved residues were important for the aldol addition step. We made 
alanine substitutions to thiol pocket residues (Figure 3.1D), as well as a P252G 
substitution and phenylalanine substitutions of Tyr220 and Ty4326. We assayed these 
HMGS variants for activity and ACP affinity using the methods described above (Table 
3.2). 
Table 3.2 Thiol pocket substitutions. 
 HMGS activity1 
(% conversion) 
ACPD Kd2 (μM) ACPA Kd2 (μM) 
WT 78.3 ± 0.9 0.2 ± 0.1 8 ± 2 
D200A < 53 -- 9 ± 4 
S216A < 5 1.1 ± 0.5 10 ± 2 
L217A < 5 2.3 ± 0.7 19 ± 6 
Y220A 21 ± 2 22 ± 17 16 ± 6 
Y220F 58 ± 2 6 ± 2 49 ± 14 
P252G < 5 17 ± 13 -- 
M256A 23.9 ± 0.8 2 ± 1 5 ± 1 
Y326A < 5 100 ± 40 12 ± 5 
Y326F 84 ± 4 17 ± 5 11 ± 2 
S328A 21 ± 1 0.9 ± 0.3 5.6 ± 0.8 
 
1Conversion of equimolar acetyl-ACPD and acetoacetyl-ACPA to HMG-ACPA in 7 min at 25 °C, averaged 
for 3 reactions. 
2Affinity was measured by fluorescence polarization using Bodipy-FL conjugated ACPs. 
3Approximate detection limit was 1 μM acyl-ACPA, or less than 5% conversion of substrate to product. 
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 Several residues in the thiol pocket were essential to HMGS activity. HMGSY220F 
and HMGSY326F had activity similar to wild-type, with only a ~25% reduction in activity 
from Y220F.  We did observe a ~85 fold reduction in the affinity of HMGSY326F for ACPD, 
presumably due to the loss of the hydrogen-bond of Tyr326 to Asp200. Due to the 
complete loss of HMGS activity from some other thiol pocket substitutions, we tested 
acetyl transfer from ACPD to these HMGS variants to determine whether donor transfer 
and/or aldol addition was impaired (Figure 3.4). 
 
Figure 3.4 Deacetylation of ACPD by HMGS. Mixtures of 20 μM acetyl-ACPD and 50 
μΜ HMGS were incubated for 30 sec at 25 °C, then acidified with formic acid and 
analyzed by LC-MS with Ppant ejection59. The percent of Ppant ions loaded with acetyl 
was averaged for three replicate incubations with each HMGS variant, then subtracted 
from a no-enzyme control to calculate percent deacetylation. 
 
 We observed no activity from HMGSY326A and a 4-fold reduction in activity from 
HMGSY220A. Tyr220 appears more directly involved in interaction with the ACPD-Ppant 
thiol and makes a hydrogen bond to the His250 backbone carbonyl, while Tyr326 sits 
more deeply in the active site, makes a hydrogen bond to Asp200, and packs against 


















with ACPA, although the alanine substitution was more deleterious to HMGS activity. 
HMGSS328A also displayed a 4-fold decrease in HMGS activity, presumably due to the 
role of the Ser328 amide in stabilizing the donor enolate intermediate. 
Leu217 appears to make a hydrophobic contact and to play a role in packing of 
the thiol pocket around the Ppant. We observed a ~4-fold decrease in ACPD affinity, a 2-
fold decrease in ACPA affinity, no HMGSL217A activity, and increased donor-transfer, 
supporting a role in either active site organization or Ppant positioning, but not in ACP 
interaction. HMGSS216A similarly had no activity, unimpaired donor-transfer, and wild-
type affinities for ACPD and ACPA. Ser216 makes a hydrogen bond to both the ACPD-
Ppant thiol and the Asp200 carboxylate. Asp200 also makes a hydrogen bond to Tyr326 
and HMGSD200A was inactive. HMGSD200A shows a ~3-fold decrease in donor-transfer, 
though deficient donor-transfer does not explain lack of overall activity, as HMGSY220A 
displayed negligible donor-transfer but a more robust conversion of acetoacetyl-ACPA to 
HMG-ACPA. 
The final two tested substitutions, P252G and M256A were both deleterious to 
HMGS activity. Pro252, in addition to interacting with the ACPD Ppant is near the 
catalytic His250. Whereas HMGSM256A had a 4-fold reduction in activity and a modest 
decrease in ACPD affinity, HMGSP252A was inactive, had a 50-100 fold decrease in ACPD 
affinity, and the ACPA interaction was too weak to fit the fluorescence anisotropy data. 
 Role of the HMGS flexible loop region. The most obvious structural difference 
between HMGS and HMGCS is a flexible loop that includes an insertion in HMGS 
relative to HMGCS90. We were interested in determining whether this region may 
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become ordered upon ACPA binding and play a role in ACP selectivity, so we designed 
substitutions (Table 3.3) to disrupt the “EGGE” motif (residues 152-155), the π-stack 
that orders upon ACPD interaction, and several other conserved residues. We previously 
observed reductions in activity and ACPD affinity from alanine substitutions to charged 
residues that interact with the ACP90. We generated E152A and E155A variants of 
HMGS under the assumption that the substitutions would be similarly deleterious to 
HMGS activity and ACPA affinity if the glutamates interact with ACPA. We made 
substitutions to Gly153 and Gly154 to cause steric clashes or to eliminate flexibility 
conferred to this loop. F148A, W161A, and Y159A substitutions were made to eliminate 
contributions to the π-stack comprising these residues. We identified five other positions 
in the flexible loop region that are conserved in sequences for HMGS but not for 
HMGCS (Appendix 1). We substituted two hydrophobic residues with aspartate (L149D, 
I157D), a conserved aspartate with alanine (D160A), and two other conserved charged 




Table 3.3 Flexible loop substitutions. 
 HMGS activity1 
(% conversion) 
ACPD Kd2 (μM) ACPA Kd2 (μM) 
WT 78.3 ±0.9 0.2 ± 0.1 8 ± 2 
EGGE motif 
E152A 68 ± 2 9 ± 9 14 ± 7 
G153F 76 ± 1 3 ± 2 4 ± 2 
G154P 57 ± 2 16 ± 5 16 ± 4 
G154F 47.5 ± 0.7 0.7 ± 0.3 8 ± 2 
E155A 59 ± 1 13 ± 10 6 ± 2 
π - stack 
F148A 92.4 ± 0.6 5 ± 2 5 ± 2 
W161A 75 ± 3 1.1 ± 0.5 13 ± 1 
Y159A 25 ± 4 0.5 ± 0.2 8 ± 2 
Other conserved residues 
R147L 50 ± 3 1.6 ± 0.8 6 ± 4 
L149D 91 ± 1 13 ± 8 1 ± 0.7 
I157D 58 ± 3 2 ± 1 7 ± 2 
D160A 72 ± 2 2.2 ± 0.9 4 ± 1 
E165R 20 ± 2 3.5 ± 0.9 5 ± 1 
1Conversion of equimolar acetyl-ACPD and acetoacetyl-ACPA to HMG-ACPA in 7 min at 25 °C, averaged 
for 3 reactions. 
2Affinity was measured by fluorescence polarization using Bodipy-FL conjugated ACPs. 
 
 
 The activity and ACP affinities of these variants indicate that in general the 
flexible loop is not essential to HMGS. The E152A, G154P, E155A substitutions resulted 
in 40-80 fold decreases in ACPD affinity but did not affect ACPA affinity. HMGSG154F did 
not affect ACP affinity but had a ~40% reduction in activity, greater than any other 
substitution to the EGGE residues. While HMGSF148A and HMGSW161A had activity 
indistinguishable from wild type, HMGSY159A had 4-fold diminished activity. None of the 
π-stack substitutions affected ACP affinities, with the exception of the F148A 
substitution, which caused a 25-fold reduction in affinity for ACPD. Of the other 
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conserved positions in the flexible loop that we studied, only Glu165 seemed to be 
important to HMGS activity, with a 4-fold reduction activity observed for HMGSE165R. 
Several of these variants had moderately reduced affinity for ACPD, with the only 
significant reduction (65-fold) coming from the L149D substitution. The data for HMGS 
activity and ACP affinity reiterate that affinity is not well correlated with activity. 
 
Discussion 
 One of our objectives for disrupting these conserved structural motifs in HMGS 
was to study ACP selectivity in the absence of a structure for the ACPA/HMGS complex. 
Affinity reductions of HMGSR33A and HMGSR33D for ACPA suggest that Arg33 contacts 
the acceptor-Ppant phosphate. The only other charged residue exposed near the ACPD-
interacting surface on HMGS was Arg262. Substitutions to other charged residues that 
were surface exposed (Table 3.1) did not cause reductions to ACPA affinity similar to 
those observed for ACPD (on the order of 10-100 fold). Competition between the two 
ACPs for HMGS interaction may indicate that the ACP binding sites are overlapping or 
that two Ppants cannot occupy the active site at once. Reduction in ACPA affinity from 
Arg262 and Arg266 substitutions suggest that that overlap may be in the basic patch of 
the HMGS surface, which ACPD binding partially occludes. In general, the ACPA-HMGS 
interaction appears to depend less strongly on electrostatic interactions as compared to 
the ACPD-HMGS interaction, which is consistent with the more subtle surface charge 
distribution of ACPA (Figure 2.9). Where ACPD has sharply contrasting areas of positive 
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and negative charge, positive charge on the helix III face of ACPA is more attenuated 
and the protein surface appears to be more hydrophobic. 
HMGS is selective between ACPD and ACPA delivered substrates, which could 
be explained by different enzyme-ACP interactions that result in different poses of the 
donor and acceptor-Ppants in the active site. Looking solely at the intermediates 
present in the active site before donor transfer and before aldol addition, a possible 
explanation becomes apparent. Cys114 attacks the acetyl thioester carbon directly 
during donor transfer, but, during aldol addition, the α-carbon of the enolate intermediate 
attacks the β-carbon of the acetoacetyl acceptor (Figure 2.1). Thus, the ACPD-Ppant 
must, by necessity, reach farther into the active site than the ACPA-Ppant. In our 
previous tests of ACP selectivity by the curacin A HMGS90, we observed weak activity 
when both the donor and acceptor substrates were presented by ACPD and no activity 
when both were on ACPA. If the above reasoning stands, this could be because the 
ACPA-Ppant may not reach far enough into the active site to deliver an acetyl to 
Cys114. The ACPD-Ppant, however, may be able to adopt a conformation in which the 
aldol addition can occur, explaining the weak activity observed. 
 How the ACPA and ACPD interactions differ is not clarified by mutagenesis of the 
conserved HMGS flexible loop region (Appendix 3.1, residues 151-158) does not 
appear essential to HMGS activity or ACPA affinity, which does not help to clarify how 
ACPA interaction differs from ACPD interaction. The π-stack formed in the HMGS-flexible 
loop is not important to HMGS activity. Only HMGSY159A had a significant (4-fold) 
reduction to activity, and no substitution seemed to affect ACPD or ACPA affinity, which 
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may be due to interaction with the ACPA Ppant that is not disrupted by loss of Trp161 or 
Asp160. 
Curiously, residues that were disordered in holo-ACPD/HMGS complex structures 
appeared to influence ACPD affinity. Both Glu152 and Glu155 were disordered, yet 
alanine variants at these positions had 20-30 fold reduced affinity for ACPD. HMGSD30A 
and HMGSR103A displayed similar reductions in ACPD affinity, even though these 
residues also appear not make direct electrostatic interactions with ACPD. Loss of 
affinity from these substitutions may come from disruption of other residues that are 
more directly responsible from ACPD interaction, or from a defect in the overall 
electrostatic landscape of the surface surrounding the active site entrance. HMGSG154P 
also exhibited reduced affinity for ACPD, again presumably to disruption of other 
residues that interact with ACPD. This may also explain the loss of activity in 
HMGSE165R. Glu165 is ordinarily involved in a salt bridge with Arg27, to which the 
substituted Arg165 would be repulsive, which could indirectly have an effect on the 
catalytically essential Arg33. 
 Of the studied variants of HMGS, those that target the “thiol pocket” region had 
the greatest effect on HMGS activity and ACP affinities. We observed that each of the 
two tyrosine residues (Tyr220 and Tyr326) was important. Phenylalanine substitutions 
of both of these residues indicate that that the hydrogen bonds from Tyr220 to His250 
and from Tyr326 to Asp200 are not essential. Complete elimination of the side chains by 
alanine substitution in both cases resulted in nearly complete loss of donor transfer. 
Neither protein was unstable, so instead these deficiencies in donor transfer support our 
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previously assigned role to the thiol pocket. The Ppant is very well ordered in holo-
ACPD/HMGS complex structures and distal from the catalytic thiol, so these residues 
may help to occlude the acetyl-Ppant before transfer. Variants of Tyr220 and Tyr326 
also exhibited reductions in ACPD and ACPA affinity. This could be due to mispositioning 
of other residues due to loss of the bulky side chain, which could also occur for 
catalytically relevant residues that are near the tyrosines, including Ser328, Cys114, 
and His 250. 
 The Asp200 and Ser216 pair was also critical to activity. Ser216 is hydrogen-
bonded to the holo Ppant thiol, but HMGSS216A had unimpaired donor transfer. Loss of 
activity should then be attributed to the aldol addition step. In structures of human 
HMGCS in complex with HMG-CoA71 (2WYA), Ser258, which is analogous to the HMGS 
Ser216, makes a hydrogen bond to the cysteamine amide of Ppant and does not 
interact with Asp200 (Asp263). In HMGS, an analogous interaction between Ser216 and 
the ACPA Ppant may explain loss of activity from the S216A substitution. Asp200, 
meanwhile, makes several hydrogen-bonds that could explain loss of activity in 
HMGSD200A. The carboxylate interacts with Ser216, Tyr326, and the backbone amide of 
Asp212, while the Asp200 backbone carbonyl hydrogen-bonds to Gly329. In this way, 
Asp200 may serve as a “keystone” that locks the positioning of several other loops in 
the HMGS active site. 
 Finally, the losses to HMGS activity from M256A and P252G substitutions may 
result from mispositioning of His250. Pro252 is two residues preceding His250 and sits 
4.0 Å away from the sidechain. Met256 was putatively identified to interact with ACPA by 
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docking ACPA structures to a homology model of the mupirocin HMGS45, and was 
supported by loss of pathway throughput from substitutions to its proposed partner 
residue in ACPA. In the curacin A HMGS, we do not observe a loss of ACPA affinity from 
an M256A substitution, but we do see a loss in HMGS activity. Because Met256 packs 
between Pro252 and Tyr220, the Met256 substitution may disrupt activity by indirectly 
disrupting positioning of His250. Meanwhile, the apparent non-effect of M256A on the 
ACPA interaction may be rationalized if either the ACPA tyrosine does not interact with 
Met256, as proposed, or it does but the loss of Met256 is compensated for by other 
hydrophobic residues in the vicinity, including Leu217 and Phe253. 
 Reductions to activity and ACP affinity as a result of the described substitutions 
collectively indicate that the most important factor in HMGS reactivity is Ppant 
positioning. Substittions to residues that are near Ppant in the active site had the 
greatest effects on activity. Several of these substitutions abolished HMGS activity while 
having minimal effect on donor transfer, while HMGSD200A and HMGSY220A had reduced 
donor transfer but only a 4-fold loss in activity. We conclude from this data that the aldol 
addition step is much more easily disrupted than donor transfer. Intuitively this makes 
sense, since the aldol addition requires stabilization of an enolate nucleophile by Glu82 
and Ser328 and precise positioning of the enolate to attack the acetoacetyl elecrophile. 
Ironically, ACPD is capable of presenting an acceptor substrate that is suitably 
positioned for this more difficult step, while the ACPA is incapable of transferring acetyl 
to Cys114.  
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As we have several times stated, HMGS variants that affect activity do not 
necessarily affect ACP affinities, and vice versa, but based on the observed ACP 
selectivity by HMGS changes in the conformation of ACP binding translate to changes 
in Ppant positioning. Several variants (R262A, R266A, R33A, R33D) that diminish ACPA 
binding and also affect activity may do so by indirectly affecting Ppant positioning by 
affecting ACPA binding. Moreover ACPA is recognized by each of the other β-branching 
enzymes, and, based on what is currently known about enzyme ACP interactions47, 
likely does so with approximately the same surface by which it interacts with HMGS. By 
further characterization of the ACPA/HMGS complex one may glean information about 
the distinguishing features of the ACP that β-branching enzymes recognize. 
Methods 
Protein expression and purification 
Plasmids encoding the curacin A HMGS90, ACPA49, and ACPD90, were expressed 
E. coli BL21 (DE3). Cultures were grown in terrific broth (TB) at 37 °C to an OD600 of 1, 
cooled 1 hour to 20 °C, then induced with 200 μM IPTG. pHMGScur90 was coexpressed 
with pGro775, which was induced with 2 g/L arabinose at an OD600 of 0.3. Cell pellets 
were lysed by resuspending in 4 mL/g buffer, incubating for 30 minutes at room 
temperature with 1 mg/mL lysozyme, 2 mM MgCl2, and 0.1 mg/mL DNase, followed by 
cooling on ice and sonication. Lysis buffer components were as follows: 50 mM 
ammonium sulfate, 50 mM HEPES pH 7.0, 20 mM imidazole, and 10% v/v glycerol for 
HMGS; 300 mM NaCl, 50 mM Tris pH 7.5, 20 mM imidazole, and 10% v/v glycerol for 
ACPA; and 300 mM NaCl, 20 mM imidazole, and 50 mM PBS pH 7.5 for ACPD. Proteins 
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were purified by immobilized metal affinity chromatography on a 5 mL His Trap column 
(GE Healthcare) by a 50 mL gradient of 20 to 400 mM imidazole, followed by size 
exclusion chromatography (SEC). HMGS was purified by SEC on a Superdex S200 
column (GE Healthcare) with a buffer of 50 mM ammonium sulfate, 20 mM HEPES pH 
7.0, and 10% v/v glycerol (Buffer H). ACPs were purified by SEC on a Superdex S75 
column (GE Healthcare) with a buffer of 150 mM NaCl, 50 mM Tris pH 7.5, and 10% v/v 
glycerol (Buffer A). Purified proteins were flash cooled in liquid N2 and stored at -80 °C. 
Site directed mutagenesis 
pHMGScur mutants were generated by PCR with overlapping primers (Table 
3.4). 0.2 ng/μL of pHMGScur, 150 nM sense and 150 nM antisense primer, 0.02 U/μL 
KOD Hot Start polymerase (Novagen), and 0.2 mM dNTPs (Novagen), in 1X KOD buffer 
(Novagen), 2mM MgSO4, and 10% v/v DMSO. The program was 18 cycles of 20 sec 
melting at 95 °C, 10 sec annealing at 60 °C, and 3 min extension at 70 °C. After PCR, 
0.2 U/μL DpnI (NEB) was added to each reaction mixture and incubated for 3 hr at 37 
°C. E. coli XL1-Blue cells were transformed with 2 μL digested PCR mixtures. Mutant 
expression constructs were purified by miniprep kit (Qiagen), and the mutations were 
verified by Sanger sequencing. 
Table 3.4 Mutagenic primers 












































































































































































 ACPs purified in the apo state were loaded in vitro using B. subtilis 
phosphopantetheinyl transferase (Sfp). ~200 μM purified ACP was incubated with 10 
mM MgCl2, 50 mM Tris pH 7.5, 0.2 mg/mL Sfp, 1 mM acyl-CoA, and 5% v/v glycerol 
~18 h at 4 °C, followed by SEC. 2 μM HMGS was reacted with 20 μM acetyl-ACPD and 
20 μM acetoacetyl-ACPA in 20 mM ammonium sulfate, 20 mM HEPES pH 7.0, and 2 
mM TCEP for 7 minutes at 25 °C. Reaction mixtures were quenched by addition of 5% 
v/v formic acid and analyzed by HPLC-mass spectrometry by QTOF (Agilent) with Ppant 
ejection. Reaction progress is reported as the HMG percent of the HMG- and 




FP affinity assay 
  HMGS affinity for ACPD and ACPA was measured by fluorescence anisotropy 
using a BODIPY-FL conjugated M1C variant of the curacin ACPD, as described 
previously90, or an E2020C variant of CurA ACPII (pLG00349).  HMGS was buffer 
exchanged into 5 mM NaCl and 10 mM HEPES pH 7.0 (FP Buffer) then incubated at 
various concentrations with 20 nM fluorescent ACPD or ACPA at room temperature for 
30 minutes. Fluorescence anisotropy was measured by a λEX of 485 nm and λEM of 538 
nm (Figure 2.15). The data were fit to A = Afree + (ΔAbound x [HMGS]/ (Kd+[HMGS])) 
(GraphPad Prism). ACP competition was assayed by fluorescence anisotropy using 
fluorescent ACPA. Unlabeled holo-ACPA, holo-ACPD, and HMGS were buffer exchanged 
into FP buffer. 20 nM fluorescent ACPA was incubated for 30 min with 8.8 μM HMGS 
and varying concentrations of unlabeled ACPD or ACPA. 
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Figure 3.5 Fluorescence anisotropy for ACPD and ACPA binding experiments. 
 
wt ACPa










































































































































































































































































































































































































































































































































































































































































































































































































































Conservation between HMGS and HMGCS. Sequences are numbered according to 
CurD. Boxed sequences are HMGS from PKS, unboxed are primary metabolism 
HMGCS. Red bar indicates disordered residues in HMGS (5KP5) and the green bar 
indicates residues that are disordered in the holo-ACPD-HMGS complex structure 
(5KP7). Accession codes and species for HMGS sequences are as follows: CurD 
F4Y432, M.producens 3L; VirC A4PHM8, S.virginiae; MupH Q8RL63, P.fluorescens; 
PsyI ADA82596, uncultured bacterium psy1; AprE WP_075900452, Moorea Bouillonii; 
CylF ARU81120, Cylindrospermum licheniforme; JamF Q6E7K2; M.producens; BryR 
A2CLL9, Candidatus E.sertula; OnnA Q5MP08, symbiont of T.swinhoei; DifN Q1RS50, 
B.amyloliquefaciens; PksG P40830, B.subtilis; BaeG E1UUM7, B.amyloliquefaciens; 
BatC D4NZD8, P.fluorescens; TaC Q1D5E5; M.xanthus; TaF Q1D5E8, M.xanthus; 



















Chapter 4. HMGS selectivity for non-natural donor substrates. 
 
Introduction 
 Modular polyketide synthases (PKS) are versatile enzyme assembly lines that 
synthesize chemically diverse and pharmaceutically interesting natural products50,4,5, 
including erythromycin, rapamycin, and bryostatin. Modular PKS biosynthetic pathways 
assemble these molecules by appending an acyl building block to the nascent product, 
making chemical modifications, then transferring the intermediate to the next module in 
the pathway5,6. The most common modifications before transfer involve reduction and/or 
dehydration of the β-carbonyl generated by polyketide extension (Figure 1.2). Each 
intermediate is tethered via a thioester linkage to the phosphopantetheine arm of an 
acyl carrier protein (ACP) domain within each module. Many PKS pathways encode a 
set of standalone enzymes that introduce an alkyl substitutent at the β-position (β-
branching18) instead of reducing the β-carbonyl. While most modification enzymes act in 
cis on a fused ACP-tethered substrate, β-branching enzymes act in trans, and 
recognize a specialized ACP tethered to a specific module in the pathway.  
The standard enzymes encoded by PKS β-branching cassettes are an HMG-
synthase (HMGS), which installs a carboxyalkyl branch at the β-carbon, an enoyl-CoA 
hydratase-like enzyme (ECH1), which dehydrates the resulting β-hydroxyl, and a second 
ECH2 that decarboxylates the carboxyalkyl branch18. The branch carbon originates from 
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an acetyl group that is delivered to HMGS by a standalone donor ACP (ACPD). ACPD is 
encoded in the β-branching cassette along with an unusual ketosynthase-
decarboxylase (KSDC), which generates acetyl-ACPD by decarboxylating malonyl-ACPD. 
Chemical diversification of polyketide β-branches is usually achieved by variation in the 
later steps by either extra enzymes to process the carboxyalkyl branch or versions of 
the standard enzymes with non-canonical activities (Figure 1.3). The HMGS reaction, by 
which an aldol addition of an acetyl donor to an acetoacetyl-like acceptor generates the 
initial carboxyalkyl branch (Figure 2.1), is usually non-variable.  
There are two characterized examples (leinamycin and myxovirescin) in which 
HMGS uses a propionyl donor, in both cases resulting in an unusual branch (Figure 
4.1)20,21. ACPD delivers the propionyl group to a specialized HMGS, which produces a 
methylated initial branch. Instead of a KSDC, the leinamycin biosynthetic pathway 
includes a specialized acyl-transferase/decarboxylase (AT/DC, LnmK) that directs 
formation of the propionyl-ACPD substrate for HMGS (LnmM)29. Myxovirescin 
biosynthesis involves two β-branching events, which install ethyl and methoxymethyl 
branches20. The former initiates in an analogous manner to the leinamycin branch, 
using a propionyl donor and a specialized ACPD/HMGS (TaE/TaF) pair, while the latter 
is generated using an acetyl donor and a standard ACPD/HMGS (TaB/TaC) pair. Both 
initial branches are dehydrated and decarboxylated by the same ECH1/ECH2 enzymes, 
but the acetyl-derived branch is subsequently hydroxylated and methylated to form the 
final, methoxymethyl branch. 
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Figure 4.1 Polyketide β-branching with non-canonical outcomes. β-branches are 
shown in color, with red for those generated from an acetyl donor and blue for a 
propionyl donor.  β-branching enzymes and ACPD are colored accordingly. A. Curacin A 
branching. The curacin A HMGS recognizes an acetyl-ACPD and is more typical of PKS 
HMGSs in sequence. The branch-processing enzymes include a halogenase and an 
ER* cyclopropanase, which are non-canonical. B. Leinamycin branching. HMGS 
recognizes a propionyl-loaded ACPD, creating a methylated initial branch. An ECH1 
dehydrates the β-position. The final fate of the branch is as part of a 5-membered 
heterocycle in the final product. C. Myxovirescin branching. Myxovirescin biosynthesis 
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involves two β-branching events. In the second, an HMGS similar to that of LnmM 
installs a propionyl branch, which becomes an ethyl substituent in the final natural 
product.  
 
 Compared to other HMGS sequences (Figure 3.2), LnmM and TaF have several 
substitutions to ordinarily conserved residues. LnmM and TaF lack the flexible loop that 
is characteristic of PKS HMG-ACP synthases90. In TaF these substitutions may be 
involved in distinguishing between its cognate ACPD/ACPA substrates (TaE/Ta1-M8) 
and those of TaC (TaB, Ta1-M6), as discussed in chapter 2. In examining which 
residues adapt HMGS to use a propionyl donor, we focused on three active site 
residues, Ala164, Ser167, and Met298, which are conserved among HMGS sequences 
but vary in LnmM and TaF. Ser167, which makes a hydrogen bond to Ppant, is an 
alanine in both LnmM and TaF, while Ala164 on the same helix is serine. These may 
point to different interactions with Ppant to allow reaction with a propionyl donor. Met298 
is on a loop adjacent to the catalytic cysteine in the HMGS active site and is a cysteine 
in LnmM and TaF. The presence of a smaller side chain in this position could make 
room for the extra methyl group on a propionyl-Cys intermediate.  
Engineered PKS pathways have low throughput, and one reason is that enzymes 
of the engineered pathway repeatedly encounter non-cognate substrates2,3. 
Characterizing the substrate range of these enzymes may guide rational engineering 
efforts. In particular, we are interested in how structural features in PKS enzyme active 
sites influence substrate recognition and confer non-canonical activity. We examined 
the effect of A164S, S167A, and M298C substitutions to the curacin HMGS on overall 
reactivity and acyl transfer from ACPD to HMGS with acetyl, propionyl, and butyryl 
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substrates, along with all combinations of those substitutions. We solved the structure of 
HMGSC114Q, designed as an isosteric mimic of the acetyl-HMGS intermediate, to further 
investigate how these residues may interact with a propionyl-loaded HMGS. 
 
Results 
Structure of acetyl-HMGS intermediate. Each catalytic residue in the HMGS 
active site occurs in a loop connecting two secondary structure elements in the thiolase 
fold. The same is true for Ser328, the backbone amide of which forms the HMGS 
oxyanion hole, for the flexible loop region, and for Met298. Met298 sits in the active site 
close to the catalytic cysteine (Cys114) and glutamate (Glu82) (Figure 4.2). TaF and 
LmnM have a cysteine in the Met298 position, leading us to hypothesize that the smaller 
cysteine side chain may open up room for the extra methyl of a propionyl donor. We 
generated a C114Q variant of HMGS as an isosteric mimic of the acetyl-HMGS 
intermediate to further investigate the structural role of Met298. HMGSC114Q was 
crystallized both with and with out bound holo-ACPD (Table 4.1, Figure 4.3-4). Active 
site residues were identically positioned in the wild-type and HMGSC114Q structures both 
with and without bound holo-ACPD. The lone structural difference as compared to wild-
type HMGS structures was in the enzyme-only structure, where residues 28-33 had 
discontinuous density. The same region in HMGSWT has poor density, but in the case of 
HMGSC114Q these residues could not be modeled confidently. Despite an apparent 
increase in flexibility of Arg33, Ppant bound in the same position as in the holo-ACPD-
HMGSWT complex. As expected, the Gln114 side chain carbonyl sits in the oxyanion 
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hole, making a hydrogen bond to the Ser328 backbone amide. The Met298 side chain 
packs closely with both Gln114 and the catalytic Glu82 side chain (Figure 4.2). 
 
Figure 4.2 Role of Met298 in the acetyl-HMGS intermediate. HMGS residues are 
shown in cyan, Ppant in yellow, and the HMGS active site cavity in gray. C114Q 
isosterically mimics an acetyl-Cys114 intermediate, and the side chain makes an 
expected hydrogen bond to the Ser328 backbone amide. The Gln114 side chain amide 
points to the Glu82 carboxylate in a position consistent with deprotonation of acetyl-




Table 4.1 Data collection and refinement statistics 
  HMGSC114Q Holo-ACPD/HMGSC114Q 
Wavelength (Å) 1.033 1.033 
Space Group P3121 P3121 
a,b (Å) 100.32 101.29 
c (Å) 105.89 104.91 
Data range (Å) 45.33-2.00 (2.05-2.00) 45.61-2.35 (2.43-2.35) 
Unique Reflections 42082 (3048) 26385 (2551) 
Completeness (%) 100 (100) 100 (100) 
Multiplicity 19.5 (20.0) 9.8 (10.2) 
Wilson B-factor 30.5 36.8 
Rmerge 0.078 (0.816)  0.190 (1.473) 
Average I/σi 25.1 (4.5) 9.4 (1.4) 
CC 1/2 1.00 (0.90) 1.00 (0.52) 
Rwork 0.157 0.181 
Rfree 0.176 0.219 
Protein atoms 3081 3845 
Ppant atoms -- 21 
Water/Ion atoms 155 209 
RMSD bond length (Å) 0.010 0.013 
RMSD bond angle (°) 1.35 1.63 
Average B-factors   
HMGS 40.0 41.1 
ACPD  73.6 
Ppant -- 67.5 
Water 50.5 49.0 
Ramachandran   
Favored (%) 97.4 97.1 
Generously Allowed (%) 2.6 2.7 




Figure 4.3 Ramachandran analysis of HMGSC114Q (enzyme only). 
 
MolProbity Ramachandra  analysis











































97.4% (381/391)  of  a l l  res idues  were  in  favored  (98%) regions .
100 .0% (391/391)  of  a l l  res idues  were  in  a l lowed (>99.8%) reg ions .
There  were  no  ou t l i e r s .
CurD_243_2_refmac20H.pdb ,  mode l  1
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Figure 4.4 Ramachandran analysis of Holo-ACPD/HMGSC114Q complex. 
 
MolProbity Ramachandran analysis











































 A  112 GLN
97 .1% (477/491)  of  a l l  res idues  were  in  favored  (98%) regions .
99 .8% (490/491)  of  a l l  res idues  were  in  a l lowed (>99.8%) reg ions .
There  were  1  out l ie rs  (phi ,  ps i ) :
     A  112 GLN (-176.6,  72.2)
CurD_316_2_refmac12H.pdb ,  mode l  1
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HMGS reaction with propionyl and butyryl substrates. CurB ACPD was 
purified in the apo state and loaded in vitro with acyl-Ppant from acetyl, propionyl, or 
butyryl-CoA. Equimolar acyl-ACPD and acetoacetyl-ACPA90 (20 μM) were mixed with 2 
μM variants of CurD HMGS for a 30 minute reaction at 25 °C. Reactions were quenched 
by addition of formic acid, and mixtures were analyzed by LC-MS for detection of 
substrate (acetoacetyl-Ppant) and product ions59 (Figure 4.5). We tested wild-type 
curacin A HMGS, as well as variants at the Ala164, Ser167, and Met298 positions 
designed based on LnmM and TaF sequences. 
 
Figure 4.5 HMGS activity with a propionyl donor. Percent conversion is shown of 
acetoacetyl-ACPA to HMG-ACPA or to 3-hydroxy-3,4-dimethylglutaryl-ACPA (HDMG-






















 HMGS showed robust conversion of propionyl-ACPD and acetoacetyl-ACPA to 
HDMG-ACPA in a 30 min reaction, though it was nearly four-fold less active than with its 
cognate acetyl-ACPD substrate. No reaction was observed with butyryl-ACPD for any of 
the variants tested. HMGSA164S, HMGSS167A, HMGSM298C, and HMGSM298A had reactivity 
with an acetyl donor indistinguishable from wild-type HMGS. In all cases, A164S 
reduced activity with a propionyl donor. A164S, when combined with M298 
substitutions, was the only substitution that had substantially reduced activity with 
acetyl-ACPD. HMGSA164S/M298C exhibited ~2-fold reduced production of HMG-ACPA 
(acetyl donor) and negligible production of HDMG-ACPA (propionyl donor). 
HMGSA164S/M298A displayed smaller reductions in activity than the HMGSA164S/M298C. 
HMGSS167A converted 42 ± 1% of propionyl-ACPD and acetoacetyl-ACPA to product, an 
increase over 26 ± 1% from wild type. 
The M298C and M298A substitutions also had differing effects on HMGS 
reactivity when combined with the S167A substitution. Production of HDMG-ACPA from 
reaction with HMGSS167A/M298C was indistinguishable from wild-type. HMGSS167A/M298A, 
however, had a similar gain to activity as was observed from HMGSS167A. Finally, 
HMGSA164S/S167A/M298C displayed wild-type production of HMG-ACPA and negligible 
production of HDMG-ACPA. In this triple variant, the S167A substitution rescued activity 
with acetyl-ACPD but did not significantly affect activity with propionyl-ACPD. 
 Loss of HMGS activity with a propionyl donor could be due to inefficient transfer 
of the acyl group from ACPD to HMGS and/or slower aldol addition of the propionyl 
nucleophile to acetoacetyl-ACPA. To determine whether the acyl-transfer reaction was 
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impaired, we incubated 20 μΜ acetyl, propionyl, and butyryl-ACPD with 50 μM wild type 
HMGS (Table 4.2) for 30 sec at 25 °C. The results demonstrate that acyl transfer is 
unimpaired with propionyl and butyryl donors. 
Table 4.2 Donor acyl transfer 
 Acetyl-ACPD Propionyl-ACPD Butyryl-ACPD 
Acyl transfer1 (%) 29 ± 1 59 ± 2 60.6 ± 0.4 
 
1Acyl transfer is calculated as percent of ppant ions loaded with acetyl, propionyl, or butyryl averaged over 
three incubations with HMGSWT, subtracted from a no-enzyme control. 
 
 We hypothesized that the observed increase in deacylation of propionyl and 
butyryl-ACPD could be due to overestimation of concentrations of the two protein stocks, 
and not due to increased transfer. The curacin A ACPD (CurB) has no tryptophan 
residues and does not respond linearly to Bradford assays using BSA standards, 
necessitating estimation of the concentration based on a Bradford assay using the 
curacin A ACPA (CurA ACPII) as a standard. We measured relative concentrations of 
each acyl-ACPD by comparing peak areas for the ACPD and ACPA intact protein 
masses. Using deconvoluted mass spectra from activity assays with HMGSWT, we 
calculated the relative total peak height for ACPD relative to ACPA. We determined a 
relative peak height of 4.15 ± 0.06 for acetyl-ACPD, 1.88 ± 0.04 for propionyl-ACPD, and 
1.80 ± 0.05 for butyryl-ACPD. Thus, we conclude that the reduced deacylation of acetyl-
ACPD was due to a greater abundance in the assay. We repeated the assay using a 
corrected concentration of ACPD (using the calculations above) and observed 71.8 ± 
0.6% acetyl transfer to HMGS. We also note that in all assays donor acyl-Ppant 
substrate was observed. Decreased reactivity with propionyl and butyryl substrates is a 
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result of impaired catalysis, and is not due to complete consumption of the donor 
substrate as a result of overestimating its concentration.  
Discussion 
 Structures of HMGSC114Q, the acetyl-HMGS intermediate mimic, and sequences 
of LmnM and TaF both point to the M298C substitution as possibly alleviating steric 
clashes with the larger propionyl-HMGS intermediate in LnmM and TaF. However, the 
M298C and M298A substitutions do not improve production of HDMG and may even 
diminish it, contradicting such an obvious explanation for the role of Met298. Because 
Met298 packs against both the acetyl-Cys intermediate and Glu82, the M298C and 
M298A substitutions may impair enolization in the curacin A HMGS. HMGSS167A/M298C 
and HMGSS167A/M298A show conflicting effects on HMGS activity with a propionyl donor. 
The M298C thiol may be positioned such that Glu82 is no longer in an ideal orientation 
to deprotonate the propionyl donor, whereas the M298A side chain would not disrupt 
Glu82 positioning (Figure 4.2). Alternatively, M298C may be able to commandeer 
substrate by nonproductive transfer of acetyl or propionyl from the ACPD Ppant to 
Cys298. The HMGSC114Q  structure shows that the acetyl-Cys114 carbonyl would be 
perfectly positioned in the oxyanion hole to stabilize an enolate nucleophile. An acyl-
Cys298 adduct, presumably, would not be positioned for deprotonation by Glu82, for 
stabilization by the oxyanion hole, and for attack on the β-carbonyl of the acetoacetyl 
acceptor. 
 The A164S substitution impairs HMGS activity. Hypothetically, Ser164 could be 
positioned such that it could make a hydrogen bond to Ppant, either from ACPA or 
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ACPD. Met298 substitutions paired with the A164S substitution create the most 
significant reductions to HMGS activity with acetyl and propionyl donors, supporting the 
conclusion that these substitutions both interfere with the normal HMGS mechanism. In 
general, Ppant positioning appears to be critical for HMGS activity. We previously 
observed that Ppant positioning in the ACPD/HMGS complex is dependent on acylation 
state90 (Chapter 2), and that some active site substitutions can eliminate activity without 
seriously disrupting ACP affinity (Chapter 3). We presume that the curacin A HMGS 
catalytic residues are not ideally positioned for reaction with propionyl, and the HMGS 
reaction could be additionally sensitive to improper Ppant positioning as a result of a 
hydrogen bond from A164S. Conversely, the S167A substitution could eliminate a 
hydrogen bond to the acetoacetyl-Ppant and increase its flexibility, allowing it to adopt a 
more favorable position for reaction with a propionyl donor. 
 Although the A164S, S167A, and M298C substitutions are present in both LnmM 
and TaF, they are not sufficient to confer selectivity for a propionyl donor to the curacin 
A HMGS, which normally uses acetyl. TaF has differences from canonical HMGS 
sequences that are responsible for selecting the TaE ACPD and not TaB, the other 
ACPD in the myxovirescin biosynthetic cluster. Thus, sequences of acetyl-donating and 
propionyl-donating HMGSs contain differences responsible for ACP selectivity and 
differences that are catalytically relevant. It remains untested whether propionyl-
donating HMGSs show a catalytic preference for propionyl over acetyl. It is also 
unknown if such a catalytic preference would be due to differences in ACP interaction. 
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HMGS discriminates between ACPD  and ACPA linked substrates, so ACPs may interact 
with a propionyl-donating HMGS in a way that is optimized for the larger donor acyl. 
Of the various strategies for engineering PKS pathways, modulating the activity of 
individual domains in a PKS pathway by mutagenesis has been relatively successful in 
proof of principle2. For several classes of PKS enzymes in which some members exhibit 
altered activity, however, structural motifs that modulate the altered activity have been 
identified. Recent examples from our lab include the cyclopropanase activity of the CurF 
ER36 and control over regioselectivity of methyltransfer by the MycF 
methyltransferase91. The current results of HMGS mutagenesis reveal at least one 
position, Ser167, that can be substituted to enhance reactivity with a non-cognate 
substrate. Meanwhile the activity of other active site variants suggest that subtle 
perturbations of several substitutions may confer propionyl-selectivity to the enzyme, 
and there is no “switch” comprising only a few residues. Finally, a definitive role for the 
conserved flexible loop region of HMGS remains unknown, and a more complete 




Protein expression and purification 
E. coli BL21 (DE3) were transformed with plasmids for the curacin A HMGS90, 
ACPA49, and ACPD90. Transformed E. coli were grown in terrific broth (TB) at 37 °C to an 
OD600 of 1, cooled to 20 °C, then gene expression was induced with 200 μM IPTG. 
 109 
pHMGScur90 was coexpressed with pGro775, which was induced at an OD600 of ~0.3 
with 2 g/L arabinose. Cell pellets from pHMGScur expression were resuspended in 4 
mL/g of buffer containing 50 mM (NH4)2SO4, 50 mM HEPES pH 7.0, 20 mM imidazole, 
and 10% v/v glycerol. Pellets for ACPA were resuspended in 300 mM NaCl, 50 mM Tris 
pH 7.5, 20 mM imidazole, and 10% v/v glycerol, and those for ACPD were resuspended 
in 300 mM NaCl, 20 mM imidazole, and 50 mM PBS pH 7.5 for ACPD. 1 mg/mL 
lysozyme, 2 mM MgCl2, and 0.1 mg/mL Dnase were added to each suspension, 
followed by incubation for 30 min at room temperature, 30 min on ice, then sonication. 
Each protein was purified by immobilized metal affinity chromatography with a 5 mL His 
Trap column (GE Healthcare) using a 50 mL gradient of 20 to 400 mM imidazole (in 
addition to lysis buffer components), then size exclusion chromatography (SEC). SEC 
for HMGS was a Superdex S200 column (GE Healthcare) with a buffer of 50 mM 
(NH4)2SO4, 20 mM HEPES pH 7.0, and 10% v/v glycerol. ACPs were purified on a 
Superdex S75 (GE Healthcare) using 150 mM NaCl, 50 mM Tris pH 7.5, and 10% v/v 
glycerol. Proteins were concentrated then flash cooled in liquid N2 and stored at -80 °C. 
Site directed mutagenesis 
 pHMGScur90 mutants were made by overlapping-primer PCR. The reaction 
components were 1X KOD buffer (Novagen), 2mM MgSO4, 10% v/v DMSO, 0.2 ng/μL 
of pHMGScur, 150 nM of each primer (Table 4.3), 0.2 mM dNTPs (Novagen), 0.02 U/μL 
KOD Hot Start polymerase (Novagen). Each reaction ran for 18 cycles of 20s melting at 
95 °C, 10s annealing at 60 °C, and 3 min extension at 70 °C. 0.2 U/μL of DpnI (NEB) 
was added to each PCR mixture, then incubated for 3 hr at 37 °C. 2 μL of each digested 
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PCR mixture was transformed into E. coli XL-1 Blue cells. The mutant constructs were 
purified by miniprep (Qiagen), and checked for the target mutation by Sanger 
sequencing. Combinations of M298 mutations the A164S, S167A, or A164S/S167A 
mutations were made by PCR with the M298C or M298A primers and the corresponding 
A164S, S167A, or A164S/S167A mutant construct. 
 
Table 4.3 Mutagenic primers 





































 HMGS readily crystallizes as a triple alanine variant (K344A/Q345A/Q347A, 
AAA)78,90. The three alanine mutations were made to pHMGScur (C114Q) as previously 
described90. HMGSC114Q/AAA was crystallized as previously described90 by hanging-drop 
vapor-diffusion at 20 °C using a well solution of 6% v/v PEG 8k, 30 mM (NH4)2SO4, and 
1X MMT pH 6.5 (Qiagen). HMGSC114Q/AAA was similarly cocrystallized with a 7:1 molar 
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ratio of holo-ACPD to HMGS in a well solution of 6% v/v PEG 8k, 60 mM (NH4)2SO4, and 
1X MMT pH 6.5 (Qiagen). 
Structure solution and refinement 
Diffraction data were collected at the Advanced Photon Source (APS) GM/CA 
23ID-D and processed with XDS79. Diffraction limits were assessed using CC1/2 and I/σI 
statistics. Data were phased by rigid body refinement in refmac580,84 using HMGS and 
ACPD models (5KP5, 5KP7)90. Subsequent rounds of model-building were carried out in 
Coot86 followed by refinement in refmac with TLS85 parameters. Waters were modeled 
in coot based on FO-FC difference density and hydrogen bonding. Molprobity was used 
to validate final models and generate Ramachandran plots87. Molecular figures were 
generated in PyMOL88. 
HMGS activity assay 
 ACPs were loaded in vitro from acyl-CoAs using B. subtilis phosphopantetheinyl 
transferase (Sfp)92. ~200 μM purified ACP was incubated with 10 mM MgCl2, 50 mM 
Tris pH 7.5, 0.2 mg/mL Sfp, 1 mM acyl-CoA, and 5% v/v glycerol ~18 h at 4 °C, followed 
by SEC. 2 μM HMGS was mixed with 20 μM acetyl, propionyl, or butyryl-ACPD and 20 
μM acetoacetyl-ACPA in 20 mM ammonium sulfate, 20 mM HEPES pH 7.0, and 2 mM 
TCEP and incubated for 30 minutes at 25 °C. Reactions were quenched with 5% v/v 
formic acid. Product formation was detected by HPLC-mass spectrometry by QTOF 
(Agilent) with Ppant ejection59. Reaction progress is reported as the product percent of 
the product and acetoacetyl-Ppant ions over three replicates. 
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ACPD acyl-transfer assay 
 20 μM Acetyl, propionyl, and butyryl ACPD were mixed in equimolar quantity with 
HMGS in 20 mΜ ammonium sulfate, 20 mM HEPES pH 7.0, and 2 mM TCEP. Reaction 
mixtures were incubated for 30 sec at 25 °C, then reactions were quenched with 5% v/v 
formic acid. Reaction mixtures were analyzed by HPLC-mass spectrometry by QTOF 
(Agilent) with Ppant ejection59. The percent of Ppant ions loaded with acetyl was 
averaged for three replicates, then the percent of acetyl-Ppant ions from a no-enzyme 







Chapter 5. Conclusions and Future Directions 
Summary and Conclusions 
 Engineering natural product biosynthetic pathways has enormous potential for 
pharmaceutical production and discovery, but faces many challenges2,3. Chief among 
these is an incomplete understanding of the rules, dictated by protein structure, that 
govern substrate selectivity and interdomain interactions. Thus, structure determination 
for proteins and complexes involved in natural products biosynthesis complements 
research concerning pathway engineering. In modular polyketide synthase (PKS) 
pathways, alkyl substitution by β-branching could be a potent and versatile tool for 
creating variants of existing natural products or for creating natural product libraries. β-
branching enzymes recognize a specialized acyl-carrier protein (ACPA) in the 
pathway24,20,25,90 and are almost always standalone proteins18. Introducing a non-natural 
β-branch into a PKS pathway then involves fewer complications with incompatible 
protein-protein interfaces.  
In this thesis, we present the detailed structural and biochemical characterization 
of the hydroxymethylglutaryl synthase (HMGS) of curacin A biosynthesis (CurD). Our 
central goal at the outset of the project was to determine how differences in protein-
protein interactions between HMGS and each of the two acyl-carrier proteins (ACP) it 
recognizes lead to selectivity. Chapter 2 described the purification, structure, and ACPD-
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bound complex of HMGS, laying the groundwork for later chapters. We furthermore 
identified several important interactions between HMGS and ACPD and determined their 
effects on HMGS activity and ACPD affinity. We found that Arg33 makes a critical 
interaction with the Ppant phosphate. Asp222 caps a 310 helix III on ACPD, with D222A 
and D222R substitutions causing 4-5 fold losses in HMGS activity. Overall we observed 
that electrostatic contacts are important to the ACPD-HMGS interaction, that the ACPD 
surface has striking shape complementarity with HMGS, and that decreases in ACPD 
affinity and HMGS activity are not well correlated. Finally, we found that the ACPD Ppant 
is flexible in the active site before acetyl transfer but can position the acetyl-thiol 
proximal to the catalytic Cys114, and is rigidly positioned into a Cys114-distal “thiol 
pocket” region in the active site after acetyl-transfer. 
Chapters 3 and 4 follow up our description of the HMGS structure and examine 
the role of conserved structural motifs in HMGS and the donor acyl selectivity of HMGS. 
Most substitutions that affected ACPD interaction did not cause corresponding effects on 
ACPA affinity. However, we determined that ACPA and ACPD bind competitively to 
HMGS, and identified Arg33 and Arg262 as residues that interact with ACPA. Based on 
ACP affinity and HMGS activity changes from several substitutions to HMGS we 
conclude that differences in ACP interaction likely create different Ppant positioning for 
each ACP. We also determined that several residues in the thiol pocket identified in 
chapter 2 were essential to HMGS activity during the aldol addition step. 
We did not observe that residues of the flexible loop region were important to 
HMGS activity or ACP interaction. The A164S substitution is deleterious to HMGS 
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activity. Although the A164S and M298C substitutions were ineffective in our goal of 
engineering the CurD HMGS to efficiently react with a propionyl donor, they highlighted 
the importance of Ppant positioning. Finally, we speculate that many differences of 
LnmM or TaF from CurD may collectively reprogram the enzyme, but further structural 
characterization is needed. 
There are still outstanding questions regarding the biochemistry β-branching. It is 
not understood how ACPD is loaded in the case of cis-AT PKS pathways. While ACP 
selectivity in HMGS is well documented24,20,25,90, the specific features of ACPA that are 
recognized by HMGS and the other β-branching enzymes are unknown. Finally, β-
branching requires a pause in the PKS assembly line whereby transfer of the polyketide 
intermediate to the next module should delay to allow the branching reactions to take 
place. There are no published studies of this phenomenon, which could result from a 
unique architecture of the branch-accepting module, the often observed sequence of 
tandem ACPAs, or the differential recognition of branched vs. unbranched intermediates 
by the downstream KS. In fact, recognition of β-branches, which can be relatively large 
substituents, by downstream enzymes in general is an unexplored area of PKS 
biochemistry and could be crucial to engineering pathways by addition of β-branches. 
Future Directions 
 ACPA Interaction. We did not observe strong decreases to holo-ACPA affinities 
as a result of our HMGS substitutions, but a next step may be to measure apo-ACPA 
affinities. The effects of substitutions to residues that interact with ACPD were much 
greater for apo-ACPD than for holo-ACPD, so apo-ACPA affinities may paint a much 
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clearer picture of the protein-protein interface. The main challenge is that the apo-ACPA 
affinities for HMGS variants are expected to be lower than that of holo-ACPA, especially 
for variants that affect affinity, necessitating a much greater investment of material for 
each experiment. 
 Extensive crystallization screening of CurD HMGS with excess ACPA, excess 
ACPD, and crosslinked with ACPA via bismaleimidoethane has only ever yielded one 
crystal form and has never produced a structure with bound ACPA. It seems unlikely at 
this point that attempts to cocrystallize curacin A HMGS with ACPA will be successful. A 
future effort may be to dialyze all salt from an HMGS sample with excess holo-ACPA 
and to screen for conditions with low salt concentrations. ACPA affinity data could not be 
obtained in high salt buffer and we have observed CurD HMGS crystals in a very wide 
variety of conditions when ACPD was present. If the CurD HMGS crystal form is 
compatible with an ACPA/HMGS complex, the interaction appears to be salt dependent 
and this could be the best chance to obtain crystals. It appears, however, that CurD 
HMGS crystallization is incompatible with an ACPA/HMGS complex. The next step for 
pursuing this crystal structure would then be to explore ACPA/HMGS pairs from other 
pathways. While HMGS proteins are often insoluble under standard expression 
conditions in E. coli, coexpression of HMGS plasmids with pGro7 is broadly applicable 
for producing soluble HMGS. Finally, crystallization of the ACPA/HMGS complex could 
be circumvented entirely by using NMR to observe chemical shift perturbations of 
HMGS as a result of ACPA binding. This approach could be challenging due to the size 
of the HMGS dimer, which is 98.8 kDa, but might yield enough data to confidently dock 
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an ACPA/HMGS complex, and may additionally provide information about the flexible 
loop region. 
 HMGS reaction with a propionyl-donor. The first follow up to our activity 
assays of HMGS active site variants should be to crystallize them to more conclusively 
determine their effects on active site architecture. In chapter 4, we speculated that the 
A164S substitution may create a new hydrogen bond to Ppant and that Met298 
substitutions may disrupt the positioning of Glu82 and the acetyl-Cys114 intermediate, 
each of which could be confirmed by crystal structures.  
A second natural follow up to our assays would be to completely replace the 
flexible loop region of the CurD HMGS with a sequence from LnmM or TaF. Engineering 
this variant is straightforward by Gibson assembly, and the resulting protein may 
crystallize by the standard protocol for CurD HMGS. ACP selectivity has already been 
demonstrated for the TaF HMGS, and differences in ACPD and ACPA interaction lead to 
ACP selectivity in each characterized HMGS. Thus, differences in ACP interaction with 
an HMGS that donates propionyl may lead to greater efficiency with the propionyl donor, 
and could result from differences in the flexible loop region. 
The CurD HMGS has diminished activity with a propionyl donor, but the observed 
level of conversion is still fairly robust by the scale of other PKS enzymes, for which it is 
not uncommon to use assay times on the order of hours to days. For this reason, the 
HMGS reaction with a propionyl donor could be used as a platform to test the substrate 
range of other β-branching enzymes. In vitro assays for the curacin A and jamaicamide 
branching enzymes are well established. If it can be demonstrated that other β-
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branching enzymes still process the methylated branch generated by HMGS from a 
propionyl donor, it becomes feasible to use the previously identified propionyl-CoA 
acyltransferase/decarboxylase (AT/DC) enzyme to engineer pathways that produce 
methylated β-branches. 
PKS engineering by β-branching. Structures have now been solved of almost 
all of the standard β-branching proteins34,37,45,90, along with several proteins involved in 
the generation of nonstandard branches29,36,38. Only the ketosynthase/decarboxylase 
(KSDC), which is presumed to decarboxylate malonyl-ACPD to generate acetyl-ACPD, 
still eludes structural characterization. Nevertheless, the next important step in the β-
branching story is to attempt to engineer a pathway by introducing a branch, as well as 
to determine how β-branching interlocks with the other modules of PKS pathways. The 
ultimate goal would be to engineer a chimeric PKS module that can accept a β-branch 





Figure 5.1 Engineering PKS by addition of β-branches. A. An unaltered PKS 
module (orange) extends the polyketide intermediate, modifies the β-position, then 
transfers the intermediate to the KS of a downstream module (green). Docking domains 
are shown appended to the orange ACP and the green KS. B. A module could be 
engineered to accept a β-branch by generating a chimera in which the ACP is replaced 
by a branch-acceptor ACPA (yellow). Modification domains (in this case KR) must be 
knocked out by mutagenesis (black X). β-branching enzymes acting in trans substitute a 
methyl (red) for the β-carbonyl and the resulting branched product is transferred to the 
downstream module. C. The chimeric module may fail due to a number of different 







The most straightforward and minimally invasive approach would be to replace 
the ACP of a module with established in vitro activity with an ACPA or a tandem ACPA 
sequence, and then to knock out any modification domains by mutagenesis (Figure 
5.1B). This approach avoids disruptions to the modular architecture that could occur if 
modification domains were excised, but still generates several potential bottlenecks 
(Figure 5.1C). Luckily, each of these potential pitfalls can in theory be singled out and 
evaluated in vitro. First, KS and AT activity in the chimeric module can be compared to 
the wild-type module to determine the compatibility of the ACPA to react with these 
domains. Substrate dependent localization of the ACP to specific domains has been 
previously observed14 and could stall the ACPA at the knocked out KR. This possibility 
can be tested by loading the chimeric module with acetoacetyl, testing for HMGS 
reactivity, and then comparing to activity with the ACPA-docking domain (ACPA-dd) 
alone. 
Bottlenecks may also occur due to incompatibility of the ACPA or the branched 
substrate with the downstream KS. Efficient docking can be validated by fluorescence 
anisotropy, and our lab now has established protocols for this assay using fluorescently 
labeled docking domains44 or ACPA90. The ACPA-dd can also be loaded with 3-
methylcrotonyl-CoA, a commercially available analog of the “canonical” β-branched 
polyketide intermediate, and used to test both transfer of the branched intermediate to 
the downstream KS and validity of that intermediate as a substrate for the downstream 
enzymes. 
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Once these complications are controlled for, a one-pot reaction of the chimeric 
module containing an ACPA (loaded with acetoacetyl) and docking domains for a 
downstream KS, the downstream KS, and the β-branching enzymes can be used to test 
the feasibility of producing an unnatural β-branch. This assay will test for potential 
bypass of the β-branching enzymes that could occur (Figure 5.1). One could then 
expand this scheme to test branching of longer polyketide intermediates, and, much 
further down the line, proceed to genetic engineering of the unnatural β-branch. 
Outstanding questions about initiation of β-branching. Separate from ACP 
selectivity, the acceptor-acyl selectivity of HMGS has not been tested. Several PKS 
pathways include an HMGS that acts upon more than one intermediate, with some 
installing up to five branches22,23. This necessitates that the HMGS active site be able to 
accommodate long acyl chains without compromising positioning of the β-carbonyl for 
aldol addition. Selectivity may be tested by loading ACPA with extended β-keto acyl 
groups and assaying for activity against a panel of HMGS enzymes. A second approach 
would be to pursue structures of HMGS enzymes that act more than once in a 
biosynthetic pathway. 
A second open area for investigation is ACPD loading with malonyl in cis-AT 
pathways. While embedded ATs are proposed as potential loading enzymes this 
hypothesis is untested. Due to the characterization of the propionyl-specific 
acyltransferase/decarboxylase (AT/DC) enzyme of leinamycin biosynthesis, the KSDC 
enzyme encoded in most β-branching cassettes warrants examination. The proposed 
decarboxylation activity of this enzyme has been established, but there are no published 
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tests for acyl-transferase activity. KSDC is sometimes referred to as a “KSQ”, but this is 
somewhat misleading (for example reference 46). The “Q” refers to a substitution in the 
active site of loading KS enzymes of the catalytic cysteine for a glutamine. KSDC 
enzymes from β-branching cassettes actually have a cysteine to serine substitution and 
furthermore are highly distinct from other KS sequences. We presume that some of 
these differences confer ACPD selectivity to the enzyme, but their catalytic implications 
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